OXADIAZOLES AS FUNGICIDES

FIELD OF THE INVENTION:

The present invention relates to novel oxadiazoles, their N-oxides, metal complexes, isomers, polymorphs and/or the agriculturally acceptable salts thereof and to a process for preparing the same. Further, the present invention relates to a combination and to compositions comprising novel oxadiazoles of the present invention. Still further, the present invention relates to the use of novel oxadiazoles for controlling or preventing phytopathogenic fungi and to a method for controlling or preventing harmful phytopathogenic fungi.

BACKGROUND:

Oxadiazoles have already been disclosed in the literature. For example in JP56065881, JP63162680, JPS6061573, JPS6296480, JPS6051188, JP2005336101, W02005051932, EP3165093, EP3165094, EP3167716, EP3165093, JP2017190296, US4488897, WO2015185485, WO2017055469,

WO2017055473, WO2017076739, W02017076740, W02017081311, W02017085098, W02017085100, W02017093019, WO2017093348, WO2017102006, W02017103219, WO2017103223, WO2017109044, W02017110861, WO2017110862, WO2017110863, WO2017110864, WO2017110865, WO2017111152, WO2017118689, WO2017148797, WO2017157962, WO2017162868, WO2017169893, WO2017174158, WO2017178245, WO2017178549, WO2017198852, WO2017207757, WO2017211649, W02017211650, WO2017211652, WO2017213252, WO2017220485, WO201772247, WO201776742,

WO201776757, WO201776935, W0201781309, W0201781310, WO201781311, WO201781312, WO2018015447, WO2018015449, WO2018015458, W02018056340, WO2018055135,

W02018080859, WO2018118781, WO2018117034, WO2018153730 and WO2018114393, various oxadiazoles have been disclosed.

The oxadiazoles reported in the above literature have disadvantages in certain aspects, such as that they exhibit a narrow spectrum of application, or they do not have satisfactory fungicidal activity, particularly at low application rates.

Therefore, it is an object of the present invention to provide compounds having an improved/enhanced activity and/or a broader activity spectrum against phytopathogenic fungi.

This objective is achieved by the use of novel oxadiazoles of the present invention for controlling or preventing phytopathogenic fungi.

SUMMARY:

The present invention relates to novel oxadiazoles of Formula I.

Formula I

wherein, R1, L1, A1, A2, A3, A4, L2 and R2 are as defined in the detailed description.

The compound of Formula I have now been found to have advantages over the compounds reported in the literature in either of improved fungicidal activity, broader spectrum biological activity, lower application rates, biological or environmental properties, and/or enhanced plant compatibility.

More specifically, the present invention further relates to combinations comprising novel oxadiazoles and at least one further pesticidally active substance for controlling or preventing phytopathogenic fungi which are difficult to control or prevent.

The present invention still further relates to compositions comprising novel oxadiazoles or novel oxadiazoles in combination with further pesticidally active substances.

The present invention still further relates to a method and use of novel oxadiazoles, of combinations or of compositions thereof for controlling and or preventing plant diseases, particularly phytopathogenic fungi.

DETAILED DESCRIPTION:

DEFINITIONS:

The definitions provided herein for the terminologies used in the present disclosure are for illustrative purpose only and in no manner limit the scope of the present invention disclosed in the present disclosure.

As used herein, the terms “comprises”, “comprising”, “includes”, “including”, “has”, “having”, “contains”,“containing”,“characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process or method.

The transitional phrase“consisting of’ excludes any element, step or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase“consisting of’ appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

The transitional phrase“consisting essentially of’ is used to define a composition or method that includes materials, steps, features, components or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components or elements do not materially affect the basic and novel characteristic(s) of the claimed invention. The term“consisting essentially of’ occupies a middle ground between“comprising” and“consisting of’.

Further, unless expressly stated to the contrary,“or” refers to an inclusive“or” and not to an exclusive “or”. For example, a condition A“or” B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

Also, the indefinite articles“a” and“an” preceding an element or component of the present invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore“a” or“an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.

As referred to in this disclosure, the term“invertebrate pest” includes arthropods, gastropods and nematodes, helminths of economic importance as pests. The term“arthropod” includes insects, mites, spiders, scorpions, centipedes, millipedes, pill bugs and symphylans. The term“gastropod” includes snails, slugs and other Stylommatophora. The term“nematode” refers to a living organism of the Phylum Nematoda. The term “helminths” includes roundworms, heartworms, phytophagous nematodes (Nematoda), flukes (Tematoda), acanthocephala and tapeworms (Cestoda).

In the context of this disclosure“invertebrate pest control” means inhibition of invertebrate pest development (including mortality, feeding reduction, and/or mating disruption), and related expressions are defined analogously.

The term“agronomic” refers to the production of field crops such as for food, feed and fiber and includes the growth of corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye, rice, maize), leafy vegetables (e.g., lettuce, cabbage, and other cole crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g., pome, stone and citrus), small fruit (berries, cherries) and other specialty crops (e.g., canola, sunflower, olives).

The term “nonagronomic” refers to other than field crops, such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications.

Nonagronomic applications include protecting an animal from an invertebrate parasitic pest by administering a parasiticidally effective (i.e. biologically effective) amount of a compound of the present invention, typically in the form of a composition formulated for veterinary use, to the animal to be protected. As referred to in the present disclosure and claims, the terms“parasiticidal” and “parasiticidally” refers to observable effects on an invertebrate parasite pest to provide protection of an animal from the pest. Parasiticidal effects typically relate to diminishing the occurrence or activity of the target invertebrate parasitic pest. Such effects on the pest include necrosis, death, retarded growth, diminished mobility or lessened ability to remain on or in the host animal, reduced feeding and inhibition of reproduction. These effects on invertebrate parasite pests provide control (including prevention, reduction or elimination) of parasitic infestation or infection of the animal.

Compounds of the present disclosure may be present either in pure form or as mixtures of different possible isomeric forms such as stereoisomers or constitutional isomers. The various stereoisomers include enantiomers, diastereomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, and geometric isomers. Any desired mixtures of these isomers fall within the scope of the claims of the present disclosure. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other isomer(s) or when separated from the other isomer(s). Additionally, the person skilled in the art knows processes or methods or technology to separate, enrich, and/or to selectively prepare said isomers.

The meaning of various terms used in the description shall now be illustrated.

The term“alkyl”, used either alone or in compound words such as“alkylthio” or“haloalkyl” or -N(alkyl) or alkylcarbonylalkyl or alkylsuphonylamino includes straight-chain or branched Ci to C24 alkyl, preferably Ci to C15 alkyl, more preferably Ci to C10 alkyl, most preferably Ci to O, alkyl. Non limiting examples of alkyl include methyl, ethyl, propyl, 1 -methylethyl, butyl, l-methylpropyl, 2-methylpropyl, l,l-dimethylethyl, pentyl, 1 -methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, l-ethylpropyl, hexyl, l,l-dimethylpropyl, l,2-dimethylpropyl, l-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, l,l-dimethylbutyl, 1 ,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, l-ethylbutyl, 2-ethylbutyl, 1.1.2-trimethylpropyl, l,2,2-trimethylpropyl, 1 -ethyl- l-methylpropyl and l-ethyl-2-methylpropyl or the different isomers. If the alkyl is at the end of a composite substituent, as, for example, in alkylcycloalkyl, the part of the composite substituent at the start, for example the cycloalkyl, may be mono- or polysubstituted identically or differently and independently by alkyl. The same also applies to composite substituents in which other radicals, for example alkenyl, alkynyl, hydroxy, halogen, carbonyl, carbonyloxy and the like, are at the end.

The term“alkenyl”, used either alone or in compound words includes straight-chain or branched C to C24 alkenes, preferably C2 to C15 alkenes, more preferably C2 to C10 alkenes, most preferably C2 to G, alkenes. Non-limiting examples of alkenes include ethenyl, l-propenyl, 2-propenyl, l-methylethenyl, l-butenyl, 2-butenyl, 3-butenyl, 1 -methyl- l-propenyl, 2-methyl-l-propenyl, l-methyl-2 -propenyl, 2-methyl-2-propenyl, l-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1 -methyl- l-butenyl, 2-methyl- 1-butenyl, 3-methyl- l-butenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, l-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1 -dimethyl -2 -propenyl, 1, 2-dimethyl- l-propenyl,

1.2-dimethyl-2 -propenyl, 1 -ethyl- l-propenyl, l-ethyl-2-propenyl, l-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1 -methyl- l-pentenyl, 2-methyl- l-pentenyl, 3-methyl- l-pentenyl, 4-methyl- 1-pentenyl, l-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, l-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, l,l-dimethyl-2-butenyl, l,l-dimethyl-3-butenyl, 1 ,2-dimethyl-l-butenyl, 1 ,2-dimethyl-2-butenyl, l,2-dimethyl-3-butenyl, 1 ,3-dimethyl- 1 -butenyl, l,3-dimethyl-2-butenyl, l,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl- l-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-l-butenyl, 3,3-dimethyl-2-butenyl, 1 -ethyl- l-butenyl, l-ethyl-2-butenyl, l-ethyl-3-butenyl, 2-ethyl- l-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, l,l,2-trimethyl-2-propenyl, l-ethyl-l-methyl-2-propenyl, l-ethyl-2-methyl-l-propenyl and l-ethyl-2-methyl-2-propenyl and the different isomers.“Alkenyl” also includes polyenes such as 1 ,2-propadienyl and 2,4-hexadienyl. This definition also applies to alkenyl as a part of a composite substituent, for example haloalkenyl and the like, unless defined specifically elsewhere.

Non-limiting examples of alkynes include ethynyl, l-propynyl, 2-propynyl, l-butynyl, 2-butynyl, 3-butynyl, l-methyl-2-propynyl, l-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, l-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-l-butynyl, l,l-dimethyl-2-propynyl, l-ethyl -2-propynyl, l-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, l-methyl-2-pentynyl, l-methyl-3-pentynyl, l-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-l-pentynyl, 3-methyl-4-pentynyl, 4-methyl-l-pentynyl, 4-methyl-2-pentynyl, l,l-dimethyl-2-butynyl, l,l-dimethyl-3-butynyl, l,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-l-butynyl, l-ethyl-2-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl and l-ethyl-l-methyl-2-propynyl and the different isomers. This definition also applies to alkynyl as a part of a composite substituent, for example haloalkynyl etc., unless specifically defined elsewhere. The term“alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl.

The term“cycloalkyl” means alkyl closed to form a ring. Non-limiting examples include cyclopropyl, cyclopentyl and cyclohexyl. This definition also applies to cycloalkyl as a part of a composite substituent, for example cycloalkylalkyl etc., unless specifically defined elsewhere.

The term “cycloalkenyl” means alkenyl closed to form a ring including monocyclic, partially unsaturated hydrocarbyl groups. Non-limiting examples include cyclopropenyl, cyclopentenyl and cyclohexenyl. This definition also applies to cycloalkenyl as a part of a composite substituent, for example cycloalkenylalkyl etc., unless specifically defined elsewhere.

The term “cycloalkynyl” means alkynyl closed to form a ring including monocyclic, partially unsaturated groups. Non-limiting examples include cyclopropynyl, cyclopentynyl and cyclohexynyl. This definition also applies to cycloalkynyl as a part of a composite substituent, for example cycloalkynylalkyl etc., unless specifically defined elsewhere.

The term“cycloalkoxy”,“cycloalkenyloxy” and the like are defined analogously. Non limiting examples of cycloalkoxy include cyclopropyloxy, cyclopentyloxy and cyclohexyloxy. This definition also applies to cycloalkoxy as a part of a composite substituent, for example cycloalkoxy alkyl etc., unless specifically defined elsewhere.

The term“halogen”, either alone or in compound words such as“haloalkyl”, includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as“haloalkyl”, said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Non limiting examples of “haloalkyl” include chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1 -chloroethyl, l-bromoethyl, l-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fhioroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, 1 , 1 -dichloro-2,2,2-trifluoroethyl, and l,l,l-trifluoroprop-2-yl. This definition also applies to haloalkyl as a part of a composite substituent, for example haloalkylaminoalkyl etc., unless specifically defined elsewhere.

The terms“haloalkenyl”,“haloalkynyl” are defined analogously except that, instead of alkyl groups, alkenyl and alkynyl groups are present as a part of the substituent.

The term“haloalkoxy” means straight-chain or branched alkoxy groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting examples of haloalkoxy include chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, l-chloroethoxy, l-bromoethoxy, 1 -fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and l,l,l-trifluoroprop-2-oxy. This definition also applies to haloalkoxy as a part of a composite substituent, for example haloalkoxyalkyl etc., unless specifically defined elsewhere.

The term“haloalkylthio” means straight-chain or branched alkylthio groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting examples of haloalkylthio include chloromethylthio, bromomethylthio, dichloromethylthio, trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, chlorofluoromethylthio, dichlorofluoromethylthio, chlorodifluoromethylthio, 1 -chloroethylthio, 1-bromoethylthio, 1- fluoroethylthio, 2-fluoroethylthio, 2,2-difluoroethylthio, 2,2,2-trifluoroethylthio, 2-chloro-2- fluoroethylthio, 2-chloro-2,2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio, 2,2,2-trichloroethylthio, pentafluoroethylthio and l,l,l-trifluoroprop-2-ylthio. This definition also applies to haloalkylthio as a part of a composite substituent, for example haloalkylthioalkyl etc., unless specifically defined elsewhere.

Non-limiting examples of “haloalkylsulfmyl” include CF3S(0), CC1 S(0), CFsCttStO) and CF3CF2S(0). Non-limiting examples of “haloalkylsulfonyl” include CF3S(0)2, CCl3S(0)2, CF3CH2S(0)2 and CF3CF2S(0)2.

The term“hydroxy” means -OH, Amino means -NRR, wherein R can be H or any possible substituent such as alkyl. Carbonyl means -C(=0)- , carbonyloxy means -OC(=0)-, sulfinyl means SO, sulfonyl means S(0)2- The term“alkoxy” used either alone or in compound words included Ci to C24 alkoxy, preferably Ci to C15 alkoxy, more preferably Ci to C10 alkoxy, most preferably Ci to G> alkoxy. Examples of alkoxy include methoxy, ethoxy, propoxy, l-methylethoxy, butoxy, 1 -methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy, 1,1-dimethylpropoxy, 1 ,2-dimethylpropoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1 ,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1 , 1 ,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1 -ethyl- 1 -methylpropoxy and l-ethyl-2-methylpropoxy and the different isomers. This definition also applies to alkoxy as a part of a composite substituent, for example haloalkoxy, alkynylalkoxy, etc., unless specifically defined elsewhere.

The term“alkoxyalkyl” denotes alkoxy substitution on alkyl. Non-limiting examples of“alkoxyalkyl” include CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2CH2CH2OCH2 and CH3CH2OCH2CH2.

The term“alkoxyalkoxy” denotes alkoxy substitution on alkoxy.

The term“alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, propylthio, 1 -methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1-dimethylethylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 2,2-dimethylpropylthio, 1-ethylpropylthio, hexylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, 1- methylpentylthio, 2-methylpentylthio, 3-methylpentylthio, 4-methylpentylthio, l,l-dimethylbutylthio, 1 ,2-dimethylbutylthio, l,3-dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3-dimethylbutylthio, 1 -ethylbutylthio, 2-ethylbutylthio, 1 , 1 ,2-trimethylpropylthio, 1,2,2-trimethylpropylthio, 1 -ethyl- l-methylpropylthio and l-ethyl-2-methylpropylthio and the different isomers.

Halocycloalkyl, halocycloalkenyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkylcarbonyl, cycloalkylcarbonyl, haloalkoxylalkyl, and the like, are defined analogously to the above examples.

The term “alkylthioalkyl” denotes alkylthio substitution on alkyl. Non-limiting examples of “alkylthioalkyl” include -CH2SCH2, -CH2SCH2CH2, CH3CH2SCH2, CH3CH2CH2CH2SCH2 and CH3CH2SCH2CH2. “Alkylthioalkoxy” denotes alkylthio substitution on alkoxy. The term “cycloalkylalkylamino” denotes cycloalkyl substitution on alkyl amino.

The terms “alkoxyalkoxyalkyl”, “alkylaminoalkyl”, “dialkylaminoalkyl”, “cycloalkylaminoalkyl”, “cycloalkylaminocarbonyl” and the like, are defined analogously to “alkylthioalkyl” or “cycloalkylalkylamino”.

The term“alkoxycarbonyl” is an alkoxy group bonded to a skeleton via a carbonyl group (-CO-). This definition also applies to alkoxycarbonyl as a part of a composite substituent, for example cycloalkylalkoxycarbonyl and the like, unless specifically defined elsewhere.

The term “alkoxy carbonylalkylamino” denotes alkoxy carbonyl substitution on alkyl amino. “Alkylcarbonylalkylamino” denotes alkyl carbonyl substitution on alkyl amino. The terms alkylthioalkoxycarbonyl, cycloalkylalkylaminoalkyl and the like are defined analogously.

Non-limiting examples of“alkylsulfinyl” include methylsulphinyl, ethylsulphinyl, propyl sulphinyl, 1-methylethylsulphinyl, butylsulphinyl, l-methylpropylsulphinyl, 2-methylpropylsulphinyl, 1,1-dimethylethylsulphinyl, pentylsulphinyl, 1 -methylbutylsulphinyl, 2-methylbutylsulphinyl, 3-methylbutylsulphinyl, 2,2-dimethylpropylsulphinyl, 1 -ethylpropylsulphinyl, hexylsulphinyl, 1,1-dimethylpropylsulphinyl, 1 ,2-dimethylpropylsulphinyl, 1 -methylpentylsulphinyl, 2 methylpentylsulphinyl, 3-methylpentylsulphinyl, 4-methylpentylsulphinyl, U -dimethylbutylsulphinyl, 1 ,2-dimethylbutylsulphinyl, 1 ,3-dimethylbutylsulphinyl, 2,2-dimethylbutylsulphinyl, 2 , 3 -dimethylbutylsulphinyl, 3 , 3 -dimethylbutylsulphinyl, 1 ethylbutylsulphinyl, 2-ethylbutylsulphinyl, 1 , 1 ,2-trimethylpropylsulphinyl, 1,2,2-trimethylpropylsulphinyl, 1 -ethyl- l-methylpropylsulphinyl and l-ethyl-2-methylpropylsulphinyl and the different isomers. The term“arylsulfmyl” includes Ar-S(O), wherein Ar can be any carbocyle or heterocylcle. This definition also applies to alkylsulphinyl as a part of a composite substituent, for example haloalkylsulphinyl etc., unless specifically defined elsewhere.

Non-limiting examples of“alkylsulfonyl” include methylsulphonyl, ethylsulphonyl, propylsulphonyl, l-methylethylsulphonyl, butylsulphonyl, 1 -methylpropylsulphonyl, 2-methylpropylsulphonyl, 1,1-

dimethylethylsulphonyl, pentylsulphonyl, l-methylbutylsulphonyl, 2-methylbutylsulphonyl, 3-methylbutylsulphonyl, 2,2-dimethylpropylsulphonyl, 1 -ethylpropylsulphonyl, hexylsulphonyl, 1,1-dimethylpropylsulphonyl, 1 ,2-dimethylpropylsulphonyl, l-methylpentylsulphonyl, 2-methylpentylsulphonyl, 3-methylpentylsulphonyl, 4-methylpentylsulphonyl, 1,1-dimethylbutylsulphonyl, l,2-dimethylbutylsulphonyl, l,3-dimethylbutylsulphonyl, 2,2-dimethylbutylsulphonyl, 2,3-dimethylbutylsulphonyl, 3,3-dimethylbutylsulphonyl, 1-ethylbutylsulphonyl, 2-ethylbutylsulphonyl, l,l,2-trimethylpropylsulphonyl, 1,2,2-trimethylpropylsulphonyl, 1 -ethyl- l-methylpropylsulphonyl and l-ethyl-2-methylpropylsulphonyl and the different isomers. The term“arylsulfonyl” includes Ar-S(0)2, wherein Ar can be any carbocyle or heterocylcle. This definition also applies to alkylsulphonyl as a part of a composite substituent, for example alkylsulphonylalkyl etc., unless defined elsewhere.

“Alkylamino”,“dialkylamino”, and the like, are defined analogously to the above examples.

The term“carbocycle or carbocyclic” includes“aromatic carbocyclic ring system” and“non-aromatic carbocylic ring system” or polycyclic or bicyclic (spiro, fused, bridged, nonfused) ring compounds in which ring may be aromatic or non-aromatic (where aromatic indicates that the Huckel rule is satisfied and non-aromatic indicates that the Huckel rule is not statisfied).

The term“heterocycle or heterocyclic” includes“aromatic heterocycle or heteroaryl ring system” and “non-aromatic heterocycle ring system” or polycyclic or bicyclic (spiro, fused, bridged, nonfused) ring compounds in which ring may be aromatic or non-aromatic, wherein the heterocycle ring contains at least one heteroatom selected from N, O, S(0)o -2, and or C ring member of the heterocycle may be replaced by C(=0), C(=S), C(=CR*R*) and C=NR*, * indicates integers.

The term “non-aromatic heterocycle” or “non-aromatic heterocyclic” means three- to fifteen-membered, preferably three- to twelve- membered, saturated or partially unsaturated heterocycle containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur: mono, bi- or tricyclic heterocycles which contain, in addition to carbon ring members, one to three nitrogen atoms and/or one oxygen or sulphur atom or one or two oxygen and/or sulphur atoms; if the ring contains more than one oxygen atom, they are not directly adjacent; non-limiting examples oxetanyl, oxiranyl, aziridinyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 1 -pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, l-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1,2,4-oxadiazolidin-3-yl, l,2,4-oxadiazolidin-5-yl, l,2,4-thiadiazolidin-3-yl, l,2,4-thiadiazolidin-5-yl, 1,2,4-triazolidin-l-yl, l,2,4-triazolidin-3-yl, l,3,4-oxadiazolidin-2-yl, l,3,4-thiadiazolidin-2-yl, 1,3,4-triazolidin-l-yl, l,3,4-triazolidin-2-yl, 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl, 2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3-dihydrothien-2-yl, 2,3-dihydrothien-3-yl, 2,4-dihydrothien-2-yl, 2,4-

dihydrothien-3-yl, pyrrolinyl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl, 2-isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxazolin-5-yl, 4-isoxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl, 2,3-dihydropyrazol-l-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol- 1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-l-yl, 4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl, 2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl,

3.4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, pyrazynyl, morpholinyl, thiomorphlinyl, l,3-dioxan-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, l,3,5-hexahydrotriazin-2-yl, 1,2,4-hexahydrotriazin-3-yl, cycloserines, 2,3,4,5-tetrahydro[lH]azepin-l- or -2- or -3- or -4- or -5- or -6-or -7- yl, 3,4,5,6-tetra-hydro[2H]azepin-2- or -3- or -4- or -5- or -6- or-7-yl, 2, 3, 4, 7-tetrahydro[lH]azepin-l- or -2- or -3- or -4- or -5- or -6- or-7- yl, 2,3,6,7-tetrahydro[lH]azepin-l- or - 2- or -3- or -4- or -5- or -6- or -7- yl, hexahydroazepin-l- or -2- or -3- or -4- yl, tetra- and hexahydrooxepinyl such as 2,3,4,5-tetrahydro[l H]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, 2,3,4,7-tetrahydro[lH]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, 2,3,6,7-tetrahydro[lH]oxepin-2-or -3- or -4- or -5- or -6- or -7- yl, hexahydroazepin-l- or -2- or -3- or -4- yl, tetra- and hexahydro-l,3-diazepinyl, tetra- and hexahydro-l,4-diazepinyl, tetra- and hexahydro-l,3-oxazepinyl, tetra- and hexahydro-l,4-oxazepinyl, tetra- and hexahydro-l,3-dioxepinyl, tetra- and hexahydro-l,4-dioxepinyl. This definition also applies to heterocyclyl as a part of a composite substituent, for example heterocyclylalkyl etc., unless specifically defined elsewhere.

The term “heteroaryl” or “aromatic heterocyclic” means 5 or 6-membered, fully unsaturated monocyclic ring system containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur; if the ring contains more than one oxygen atom, they are not directly adjacent; 5-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom; 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom as ring members, non-limiting examples furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, l,2,4-oxadiazolyl, l,2,4-thiadiazolyl, l,2,4-triazolyl, l,3,4-oxadiazolyl, l,3,4-thiadiazolyl,

1.3.4-triazolyl, tetrazolyl; nitrogen-bonded 5-membered heteroaryl containing one to four nitrogen atoms, or benzofused nitrogen-bonded 5-membered heteroaryl containing one to three nitrogen atoms: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen

atoms or one to three nitrogen atoms as ring members and in which two adjacent carbon ring members or one nitrogen and one adjacent carbon ring member may be bridged by a buta-l,3-diene-l,4-diyl group in which one or two carbon atoms may be replaced by nitrogen atoms, where these rings are attached to the skeleton via one of the nitrogen ring members, non-limiting examples l-pyrrolyl, 1-pyrazolyl, l,2,4-triazol-l- yl, l-imidazolyl, l,2,3-triazol-l-yl and l,3,4-triazol-l-yl.

6-membered heteroaryl which contains one to four nitrogen atoms: 6-membered heteroaryl groups which, in addition to carbon atoms, may contain, respectively, one to three and one to four nitrogen atoms as ring members, non-limiting examples 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, l,3,5-triazin-2-yl, l,2,4-triazin-3-yl and l,2,4,5-tetrazin-3-yl; benzofused 5-membered heteroaryl containing one to three nitrogen atoms or one nitrogen atom and one oxygen or sulphur atom: non-limiting examples indol-l-yl, indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, benzimidazol-l-yl, benzimidazol-2-yl, benzimidazol-4-yl, benzimidazol-5-yl, indazol-l-yl, indazol-3-yl, indazol-4-yl, indazol-5-yl, indazol-6-yl, indazol-7-yl, indazol-2-yl, l-benzofuran-2-yl, l-benzofuran-3-yl, l-benzofuran-4-yl, l-benzofuran-5-yl, l-benzofuran- 6-yl, l-benzofuran-7-yl, l-benzothiophen-2-yl, l-benzothiophen-3-yl, 1-benzothiophen-4-yl, 1- benzothiophen-5-yl, l-benzothiophen-6-yl, l-benzothiophen-7-yl, 1,3-benzothiazol-2-yl, 1,3- benzothiazol-4-yl, l,3-benzothiazol-5-yl, l,3-benzothiazol-6-yl, 1,3-benzothiazol-7-yl, l,3-benzoxazol-2-yl, l,3-benzoxazol-4-yl, l,3-benzoxazol-5-yl, l,3-benzoxazol-6-yl and l,3-benzoxazol-7-yl; benzofused 6-membered heteroaryl which contains one to three nitrogen atoms: non-limiting examples quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-l-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl.

The term“trialkylsilyl” includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom such as trimethylsilyl, triethylsilyl and t-butyl-dimethylsilyl. “Halotrialkylsilyl” denotes at least one of the three alkyl radicals is partially or fully substituted with halogen atoms which may be the same or different. The term”alkoxytrialkylsilyl” denotes at least one of the three alkyl radicals is substituted with one or more alkoxy radicals which may be the same or different. The term“trialkylsilyloxy” denotes a trialkylsilyl moiety attached through oxygen.

Non-limiting examples of “alkylcarbonyl” include C(=0)CH3, C^OjCttCttCth and C(=0)CH(CH3)2- Non-limiting examples of“alkoxycarbonyl” include CH30C(=0), CthCttOC^O), CthCthCthOC^O), (CH3)2CH0C(=0) and the different butoxy -or pentoxycarbonyl isomers. Non limiting examples of “alkylaminocarbonyl” include CH3NHC(=0), CthCttNHC^O), CH3CH2CH2NHC(=0), (CH3)2CHNHC(=0) and the different butylamino -or pentylaminocarbonyl isomers. Non-limiting examples of “dialkylaminocarbonyl” include (CH3)2NC(=0), (CH3CH2)2NC(=0), CH3CH2(CH3)NC(=0), CH3CH2CH2(CH3)NC(=0) and (CH3)2CHN(CH3)C(=0). Non-limiting examples of “alkoxyalkylcarbonyl” include CThOCttC^O), CthOCttCthC^O),

CH3CH20CH2C(=0), CH3CH2CH2CH20CH2C(=0) and CH3CH20CH2CH2C(=0). Non-limiting examples of “alkylthioalkylcarbonyl” include CH3SCH2C(=0), CH3SCH2CH2C(=0), CH3CH2SCH2C(=0), CH3CH2CH2CH2SCH2C(=0) and CH3CH2SCH2CH2C(=0). The term haloalkylsufonylaminocarbonyl, alkylsulfonylaminocarbonyl, alkylthioalkoxycarbonyl, alkoxycarbonylalkyl amino and the like are defined analogously

Non-limiting examples of “alkylaminoalkylcarbonyl” include CH3NHCH2C(=0), CH3NHCH2CH2C(=0), CH3CH2NHCH2C(=0), CH3CH2CH2CH2NHCH2C(=0) and CH3CH2NHCH2CH2C(=0).

The term“amide” means A-R'C=ONR"-B, wherein R' and R" indicates substituents and A and B indicate any group.

The term“thioamide” means A-R'C=SNR"-B, wherein R' and R" indicates substituents and A and B indicate any group.

The total number of carbon atoms in a substituent group is indicated by the“Ci- ” prefix where i and j are numbers from 1 to 21. For example, Ci-C3 alkylsulfonyl designates methylsulfonyl through propylsulfonyl; C2 alkoxyalkyl designates CH3OCH2; C3 alkoxyalkyl designates, for example, CH3CH(OCH3), CH3OCH2CH2 or CH3CH2OCH2; and CT alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH3CH2CH2OCH2 and CH3CH2OCH2CH2. In the above recitations, when a compound of Formula I is comprised of one or more heterocyclic rings, all substituents are attached to these rings through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen. When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents. Further, when the subscript m in (R)m indicates an integer ranging from for example 0 to 4 then the number of substituents may be selected from the integers between 0 and 4 inclusive.

When a group contains a substituent which can be hydrogen, then, when this substituent is taken as hydrogen, it is recognized that said group is being un-substituted.

The embodiments herein and the various features and advantageous details thereof are explained with reference to the non-limiting embodiments in the description. Descriptions of well -known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skilled in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein.

The description of the specific embodiments will so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein.

Any discussion of documents, acts, materials, devices, articles and the like that has been included in this specification is solely for the purpose of providing a context for the disclosure. It is not to be taken as an admission that any or all of these matters form a part of the prior art base or were common general knowledge in the field relevant to the disclosure as it existed anywhere before the priority date of this application.

The numerical values mentioned in the description and the description/claims though might form a critical part of the present invention of the present invention, any deviation from such numerical values shall still fall within the scope of the present invention if that deviation follows the same scientific principle as that of the present invention disclosed in the present invention.

The inventive compound of the present invention may, if appropriate, be present as mixtures of different possible isomeric forms, especially of stereoisomers, for example E and Z, threo and erythro, and also optical isomers, but if appropriate also of tautomers. Both the E and the Z isomers, and also the threo and erythro isomers, and the optical isomers, any desired mixtures of these isomers and the possible tautomeric forms are disclosed and claimed.

The term“pest” for the purpose of the present disclosure includes but is not limited to fungi, stramenopiles (oomycetes), bacteria, nematodes, mites, ticks, insects and rodents.

The term“plant” is understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant cultivars which are protectable and non -protectable by plant breeders’ rights.

For the purpose of the present disclosure the term“plant” includes a living organism of the kind exemplified by trees, shrubs, herbs, grasses, ferns, and mosses, typically growing in a site, absorbing water and required substances through its roots, and synthesizing nutrients in its leaves by photosynthesis.

Examples of“plant” for the purpose of the present invention include but are not limited to agricultural crops such as wheat, rye, barley, triticale, oats or rice; beet, e.g. sugar beet or fodder beet; fruits and fruit trees, such as pomes, stone fruits or soft fruits, e.g. apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus fruit and citrus trees, such as oranges, lemons, grapefruits or mandarins; any horticultural plants, vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such as avocados, cinnamon or camphor; cucurbitaceae; oleaginous plants; energy and raw material plants, such as cereals, corn, soybean, other leguminous plants, rape, sugar cane or oil palm; tobacco; nuts; coffee; tea; cacao; bananas; peppers; vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broad-leaved trees or evergreens, e.g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants.

Preferably, the plant for the purpose of the present invention includes but is not limited to cereals, corn, rice, soybean and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, any horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar cane, cotton, potato, tomato, onions, peppers and vegetables, ornamentals, any floricultural plants and other plants for use of human and animals.

The term“plant parts” is understood to mean all parts and organs of plants above and below the ground. For the purpose of the present disclosure the term plant parts includes but is not limited to cuttings, leaves, twigs, tubers, flowers, seeds, branches, roots including taproots, lateral roots, root hairs, root apex, root cap, rhizomes, slips, shoots, fruits, fruit bodies, bark, stem, buds, auxiliary buds, meristems, nodes and internodes.

The term“locus thereof’ includes soil, surroundings of plant or plant parts and equipment or tools used before, during or after sowing/planting a plant or a plant part.

Application of the compounds of the present disclosure or the compound of the present disclosure in a composition optionally comprising other compatible compounds to a plant or a plant material or locus thereof include application by a technique known to a person skilled in the art which include but is not limited to spraying, coating, dipping, fumigating, impregnating, injecting and dusting.

The term“applied” means adhered to a plant or plant part either physically or chemically including impregnation.

Accordingly, novel oxadiazoles according to the present invention are represented by a compound of Formula I and include N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof.

The present invention relates to a compound of Formula I,

wherein,

R1 is selected from the group consisting of Ci-C2-monohaloalkyl, Ci-C2-dihaloalkyl, C1-C2-trihaloalkyl, Ci-C2-tetrahaloalkyl, and Ci-C2-pentahaloalkyl;

A1 is CRA1 or N;

A2 is CRA2 or N;

A3 is CRA3 or N; &

A4 is CRA4 or N; wherein no more than two of A1, A2, A3 & A4 are nitrogen;

wherein, RA1, RA2, RA3, RA4, and RA5 are independently and optionally selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, CYCYalkyl, CYCYcycloalkyl,

Ci-Ce-haloalkyl, Ci-Ce-hydroxy alkyl, Ci-Ce-alkoxy, Ci-Ce-alkoxy-Ci-Ce-alkyl, and C 1 -CY haloalkoxy;

either RA1 and RA2 or RA3 and RA4 or both RA1 and RA2 as well as RA3 and RA4 together with the atoms to which they are attached may form a 3-, 4-, 5-, or 6- membered carbocyclic ring or ring system or 4-, 5-, or 6- membered heterocyclic ring or ring system; wherein C atom ring members of the carbocyclic or the heterocyclic ring or ring system may be replaced by C(=0) or C(=S); and heteroatom in the heterocyclic ring or ring system is selected from N, O or S(0)o -2, wherein, the carbocyclic or the heterocyclic ring or ring system may optionally further be substituted with one or more of halogen, CYCYalkyl, CYCYcycloalkyl, CYCYhaloalkyl, C 1 -CYhydroxyal kyl , CYCYalkoxy and Ci-C6-haloalkoxy;L1 is -C(R4R5)- or -C(=W)-;

L2 is a direct bond, -C(R4aR5a)-, -(NR6)0-1C(=W1)-(NR6)0-1, -C(F2)-, -C(R4aR5a)C(=0)-, -O-, -(CR4aR5a)o-2S(=0)o-2-, -N(R6)-, -(CR4aR5a)o-2C(=W1)NR6(CR4aR5a)0-2-, and -NR6S(=O)0-2-;

wherein W and W1 is O or S;

wherein, R2 is selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, CYCYalkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-Cs-cycloalkyl, CYCYcycloal kylal kyl , Ci-Ce-haloalkyl, Ci-C6-alkoxy-Ci-C4-alkyl, Ci-Ce-hydroxy alkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8-halocycloalkyl, Ci-Ce-alkoxy, aryloxy, heteroaryloxy, C3-Cs-heterocylyloxy, C3-Cs-cycloalkyloxy, Ci-Ce-haloalkoxy, Ci-Ce-haloalkoxycarbonyl, Ci-Ce-alkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, Ci-Ce-haloalkylthio, C 1 - C 6 - h a 1 a 1 k y 1 s u 1 f i n y 1 , C 1 -CYhaloal kylsulfonyl , arylsulfonyl, heteroarylsulfonyl, C3-Cs-cycloalkylsulfonyl Ci-Ce-alkylsulfinyl, Ci-Ce-alkylsulfonyl, Ci-Ce-alkylamino, arylamino, heteroarylamino, C4-Cs-heterocyclylamino, Ci-Ce-dialkylamino, C3-C8-cycloalkylamino, C i-CValkyl-CVCVcycloalkylamino, C 1 -CVal kylcarbonyl , C 1 -G,-al koxycarbonyl , C3-C6-cycloalkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloxycarbonyl, C 1 -CV alkylaminocarbonyl, Ci-Ce-dialkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, C3-Ce-cycloalkylaminocarbonyl, Ci-Ce-alkylaminocarbonylamino, Ci-Ce-dialkylaminocarbonylamino, arylaminocarbonylamino, heteroarylaminocarbonylamino, C3-C6-cycloalkylaminocarbonylamino, Ci-CVal kylcarbonyl ami no, C3-C6-cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, heterocyclylcarbonylamino, Ci Ce-haloalkylcarbonylamino, C 1 -CV alkyloxycarbonylamino, aryloxycarbonylamino, heterocycloxycarbonylamino, heteroaryloxycarbonylamino, C3-C6-cycloalkyloxycarbonylamino , Ci-Ce-alkoxycarbonyloxy, C 1 -CV alkylaminocarbonyloxy, or Ci-Ce-dialkylaminocarbonyloxy, sulfilimines, sulfoximines, sulfonamide, and sulfinamide; R2 may optionally further be substituted with one or more R7; or

R2 is phenyl, benzyl, naphthyl, a 5- or 6-membered aromatic ring, an 8- to l l-membered aromatic multi-cyclic ring system, an 8- to l l-membered aromatic fused ring system, a 5- or 6-membered heteroaromatic ring, an 8- to l l-membered heteroaromatic multi-cyclic ring system or an 8- to l l-membered heteroaromatic fused ring system; wherein the heteroatom of the heteroaromatic ring or ring system is one or more heteroatom selected from N, O or S, and each phenyl, benzyl, aromatic or heteroaromatic ring or ring system may be optionally substituted with one or more substituents selected from R3; or

or R2 and R6 together with the atoms to which they are attached form a 4-, 5-, 6- or 7-membered nonaromatic heterocyclic ring, an 8- to l5-membered nonaromatic hetero-multicyclic ring system, an 5- to 15 membered hetero-spirocyclic ring system, or an 8- to l5-membered nonaromatic heterocyclic fused ring system, wherein the heteroatom of the nonaromatic heterocyclic ring or ring system is selected from N, O or S(0)o 2; and the C ring member of the nonaromatic heterocyclic ring or ring system may be replaced with C(=0), C(=S), C(=CR4bR5b) or C(=NR6a) and each or nonaromatic heterocyclic ring or ring system may be optionally substituted with one or more substituents selected from R3;

wherein, R3 is independently selected from halogen, cyano, nitro, hydroxy, CVCValkyl, C2- CValkcnyl, C2-C6-alkynyl, CVCVhaloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8- cycloalkyl, C3-Cs-halocycloalkyl, C ; C s c y c 1 a 1 k y 1 C 1 C 6 a 1 k y 1 , C3-C8-cycloalkyl-C3-Cs- cycloalkyl, C3-Cs-cycloalkenyl, C 1 -CVal koxy-C 1 -G,-al kyl , CVCVcycloalkoxy-Ci -CVal kyl, C 1 -CVal kylsulfinyl -C 1 -G,-al kyl , C 1 -CVal ky 1 su Ifonyl -C 1 -CVal ky 1 , CVCValkyl ami no, di-Ci- CValkylamino, C 1 -CVal kyl am i no-C 1 -CVal ky 1 , di-Ci-Ce-alkylamino-Ci-Ce-alkyl, C 1 -CV haloal ky 1 am ino-C 1 -CVal ky 1 , C3-C8-cycloalkylamino, CVCVcycloal kyl am i no-C 1 -CVal kyl , Ci- Ce-alkylcarbonyl, Ci-Ce-haloalkoxy-Ci-Ce-alkyl, Ci-Ce-hydroxy alkyl, C2-C6-hydroxyalkenyl, C2-C6-hydroxyalkynyl, C2-C6-alkenyloxy, C2-C6-haloalkenyloxy, C2-C6-alkynyloxy, C i -CV alkylcarbonylalkoxy, Ci-Ce-alkylthio, C i -G.-haloalkylthio, C3-Cs-cycloalkylthio, Ci-Ce-alkylsulfinyl, Ci-Ce-haloalkylsulfinyl, Ci-Ce-alkylsulfonyl, Ci-Ce-haloalkylsulfonyl, C3-C8-cycloalkylsulfonyl, C3-Cs-cycloalkylsulfinyl, C 1 - C 6 - a 1 k y 1 s u 1 f o n y 1 a m in o , Ci-Ce-haloalkylsulfonylamino, Ci-Ce-alkylsulfonyloxy, Ce-Cio-arylsulfonyloxy, Ce-Cio-arylsulfonyl, Ce-Cio-arylsulfinyl, Ce-Cio-arylthio, Ci-Ce-cyanoalkyl, Ci-Ce-haloalkylamino, C 1 -CV alkoxyamino, Ci-Ce-haloalkoxyamino, Ci-Ce-alkoxycarbonylamino, Ci-Ce-alkylcarbonyl-Ci-Ce-alkylamino, C2-C6-alkenylthio, di(Ci-C6-haloalkyl)amino-Ci-C6-alkyl, CVCV alkylaminocarbonylamino, di(Ci-C6-haloalkyl)amino, sulfilimines, sulfoximines or SF5; wherein, R3 may be optionally substituted with halogen, cyano, amino, C i-G, -alkyl, C 1 -CV alkoxy, Ci-Ce-alkylamino-Ci-Ce-alkoxy, Ci-Ce-alkylthio, and C3-Cs-cycloalkyl; or

R7 is selected from the group consisting of C i-G.-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C3-Cs-cycloalkylalkyl, Ci-Ce-haloalkyl, Ci-C6-alkoxy-Ci-C4-alkyl, C 1 -CV hydroxy alkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8-halocycloalkyl, CVG.-alkoxy, C3-C8-cycloalkyloxy, aryloxy, Ci-Ce-haloalkoxy, and Ci-Ce-haloalkoxycarbonyl; or

two R7 together with the atoms to which they are attached may form a 3-, 4-, 5-, or 6-membered carbocyclic ring or ring system or 4-, 5-, or 6- membered heterocyclic ring or ring system; wherein C atom ring members of the carbocyclic or the heterocyclic ring or ring system may be replaced by C(=0) or C(=S); and heteroatom in the heterocyclic ring or ring system is selected from N, O or S; or

R7 is phenyl, benzyl, a 5-membered aromatic ring, a 5- or 6-membered heteroaromatic ring; wherein heteroatom of the heteroaromatic ring is selected from N, O or S; or

R7 is a 3- to 7-membered nonaromatic carbocyclic ring, a 4-, 5-, 6- or 7-membered nonaromatic heterocyclic ring, wherein, the heteroatom of the nonaromatic heterocyclic ring is selected from N, O or S(0)o -2, and the C ring member of the nonaromatic carbocyclic or nonaromatic heterocyclic ring may be replaced with C(=0), C(=S), C(=CR4cR5c) or C(=NR6b);

wherein, R7 may be further substituted with one or more R4d on C atom and with one or more R6C on N atom;

R4, R4a, R4b, R4c, R4d, R5, R5a, R5b, and R5c are independently selected from hydrogen, halogen, cyano, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, C2-C4-

haloalkenyl, C2-C4-haloalkynyl, CYCVcycloalkyl, CY C - h a 1 o c y c 1 o a 1 k y 1, C3-C8- cycloalkyloxy, Ci-C4-alkoxy, and Ci-C4-haloalkoxy; or

all or either of R4 and R5; R4a and R5a; R4b and R5b; and R4c and R5c; together with the atoms to which they are attached may form a C3-C6 non-aromatic carbocylic ring or C3-C6 non-aromatic heterocylic ring;

R6, R6a, R6b, and R6c are independently selected from the group consisting of hydrogen, cyano, hydroxy, NRbRc, (C=0)-Rd, (C=0)(C=0)-Rd, S(0)o 2Re, CYCY alkyl, Ci CYhaloalkyl, Ci CYalkoxy, Ci CYhaloalkoxy, Ci CYalkylamino, di-Ci CY alkylamino, tri-Ci CYalkylamino, and C3 Cs-cycloalkyl;

Rb and Rc represent hydrogen, hydroxyl, cyano, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, C3-Cs-cycloalkyl, aryl, heteroaryl, C4-C6-heterocyclyl, and C3- C8-halocycloalkyl;

Rd represents hydrogen, hydroxy, halogen, NRbRc, Ci-Ce-alkyl, Ci CY haloalkyl, Ci CYalkoxy, Ci-Ce-haloalkoxy, C3-Cs-cycloalkyl aryloxy, heteroaryloxy, C3-Cs-cycloalkoxy, and C3-Cs-halocycloalkyl; and

Re represents hydrogen, halogen, cyano, CYCYalkyl, Ci-Ce-haloalkyl, Ci-Ce- alkoxy, Ci-Ce-haloalkoxy, C3-Cs-cycloalkyl, and C3-Cs-halocycloalkyl;

or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof. Particularly, the compound of Formula I is as defined herein after, wherein

R1 is Ci-C2-dihaloalkyl or Ci-C2-trihaloalkyl;

A1 is CRA1 or N;

A2 is CRA2 or N;

A3 is CRA3 or N; &

A4 is CRA4 or N; wherein no more than one of A1, A2, A3 & A4 are nitrogen;

wherein, RA1, RA2, RA3, RA4, and RA5 are independently and optionally selected from the group consisting of hydrogen, halogen, cyano, CYCYalkyl, C3-C6-cycloalkyl, Ci-Ce-haloalkyl, and Ci-Ce-alkoxy;

L1 is -C(R4R5)- or -C(=W)-;

L2 is -(NR6)O-IC(=W1)-(NR6)0-I, -(CR4aR5a)i-2S(=0)o-2-, -(CR4aR5a)o-2C(=W1)NR6(CR4aR5a)0-2-, and NR6-NR6S(=0)O-2-;

wherein W and W1 is O or S;

wherein, R2 is selected from the group consisting of CVCValkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, CVCVcycloal kylal kyl , Ci-Ce-haloalkyl, Ci-C6-alkoxy-Ci-C4-alkyl, Ci-Ce-hydroxyalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, CVCVhalocycloalkyl, Ci-Ce-alkoxy, aryloxy, heteroaryloxy, Cs-Cs-heterocylyloxy, C3-Cs-cycloalkyloxy, Ci-Ce-alkylthio, arylthio, heteroarylthio, C4-C8-heterocyclylamino, Ci-Ce-dialkylamino, and C3-C8-cycloalkylamino; or

R2 is phenyl, benzyl, a 5- or 6-membered heteroaromatic ring; wherein the heteroatom of the heteroaromatic ring is one or more heteroatom selected from N, O or S, and each phenyl, benzyl or heteroaromatic ring may be optionally substituted with one or more substituents selected from R3; or

or R2 and R6 together with the atoms to which they are attached form a 4-, 5- or 6- membered nonaromatic heterocyclic ring, wherein the heteroatom of the nonaromatic heterocyclic ring is selected from N or O; and nonaromatic heterocyclic ring may be optionally substituted with one or more substituents selected from R3;

wherein, R3 is independently selected from halogen, cyano, CVCValkyl, C2-C6-alkenyl, C2- CValkynyl, CVCVhaloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-Cs-cycloalkyl, C3-C8- halocycloalkyl, CVCValkyl ami no, d i - C 1 - C 6 - a 1 k y 1 a m i n , and CVCValkoxy; or

R4, R4a, R4b, R5, R5a and R5b are independently selected from hydrogen, halogen, Ci- C4-alkyl, Ci-C4-haloalkyl, C2-C4-haloalkenyl, C3-C6-cycloalkyl, C3-C6- halocycloalkyl, C3-Cs-cycloalkyloxy, Ci-C4-alkoxy, and Ci-C4-haloalkoxy; or

all or either of R4 and R5; R4a and R5a; and R4b and R5b; together with the atoms to which they are attached may form a C3-C6 non-aromatic carbocylic ring or C3-C6 non aromatic heterocylic ring;

R6 and R6a are independently selected from the group consisting of hydrogen, S(0)o 2Re, CVCValkyl, Ci CVhaloalkyl, Ci Ce-alkoxy, Ci Ce-haloalkoxy, and C3 C8- cycloalkyl;

Re represents hydrogen, CVCValkyl, CVCVhaloalkyl, CVCValkoxy, C 1 -CV haloalkoxy, C3-C8-cycloalkyl, and C3-C8-halocycloalkyl;

or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof.

More particularly, the compound is as defined hereinafter, wherein

R1 is Ci-C2-trihaloalkyl;

A1 is CH;

A2 is CH;

A3 is CH; &

A4 is CH;

L1 is -C(R4R5)- or -C(=W)-;

L2 is -(NR6)o-iC(=W1)-(NR6)0-i, -(CR4aRV i 2S(=0)o 2-, -(CR4aR5a)0-2C(=W1)NR6(CR4aR5a)0-2-, and NR6-NR6S(=0)Q-2-;

wherein W and W1 is O or S;

wherein, R2 is selected from the group consisting of CVCValkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8- cycloalkyl, CV CV c y c 1 a 1 k y 1 a 1 k y 1 , Ci-Ce-haloalkyl, Ci-C6-alkoxy-Ci-C4-alkyl, Ci-Ce-alkoxy, aryloxy, heteroaryloxy, C3-Cs-heterocylyloxy, C4-C8-heterocyclylamino, and C 1 - C 6 - d i a 1 k y 1 a m i n ; or

R2 is phenyl, benzyl, a 5- or 6-membered heteroaromatic ring; wherein the heteroatom of the heteroaromatic ring is one or more heteroatom selected from N, O or S, and each phenyl, benzyl or heteroaromatic ring may be optionally substituted with one or more substituents selected from R3; or

or R2 and R6 together with the atoms to which they are attached form a 4-, 5- or 6- membered nonaromatic heterocyclic ring, wherein the heteroatom of the nonaromatic heterocyclic ring is selected from N or O; and nonaromatic heterocyclic ring may be optionally substituted with one or more substituents selected from R3;

wherein, R3 is independently selected from halogen, cyano, Ci-Ce-alkyl, CVCVhaloalkyl, C3- C8-cycloalkyl, CVCValkyl ami no, di -C 1 -CVal ky 1 am i no, and CVCValkoxy; or

R4, R4a, R4b, R5, R5a and R5b are independently selected from hydrogen, halogen, Ci- C4-alkyl, Ci-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C3-C8- cycloalkyloxy, Ci-C4-alkoxy and Ci-C4-haloalkoxy; or

all or either of R4 and R5; R4a and R5a; and R4b and R5b; together with the atoms to which they are attached may form a C3-C6 non-aromatic carbocylic ring;

R6 and R6a are independently selected from the group consisting of hydrogen, C 1 -CV alkyl, Ci CVhaloalkyl, and C3 Cs-cycloalkyl;

or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof.

The following compounds are excluded from the scope of the present invention:

N-[4-[[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]methyl]phenyl]-methanesulfonamide [Cas No.

1128079-05-9],

N-[4-[[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]methyl]phenyl]-acetamide [Cas No. 943828-64-6], l,2,4-Oxadiazole, 3-[(2,6-dichloro-4-hydrazinylphenyl)methyl]-5-(trifluoromethyl) [Cas No. 164157-03-3], and

4-[[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]methyl]-benzoic acid methyl ester [Cas No. 2368917-79-5].

Most particularly, the compound of Formula I is selected from the group consisting of:

4-methyl-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzamide; N-(4-((5- (trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)benzamide; N-(4-((5-(trifluoromethyl)- l,2,4-oxadiazol-3-yl)methyl)phenyl)picolinamide; N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)nicotinamide; N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)isonicotinamide; 2-phenyl-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)acetamide; 4-cyano-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)benzamide; 4-(trifluoromethyl)-N-(4-((5-(tifluoromethyl)- 1 ,2,4-oxadiazol-3- yl)methyl)phenyl)benzamide; 4-fluoro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)benzamide; 4-chloro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)benzamide; 2-(4-fluorophenyl)-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)acetamide ; N-(4-fluorobenzyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; morpholino(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)methanone ; N-(3-fluorobenzyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(l-(p-tolyl)ethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(pyridin-3-ylmethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(5-chloropyridin-3-yl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(2-chloro-5-methoxyphenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(2-methoxyphenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(4-methoxyphenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(2-morpholinoethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(4-chlorophenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(3-fluorobenzyl)-N-methyl-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(isoxazol-3-yl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; 4-methoxy-N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-

carbonyl)phenyl)benz amide ; 4-chloro-N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl)benz amide ; N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl)isonicotinamide; N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl)nicotinamide; tert-butyl (4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl)carbamate; tert-butyl (4-(difluoro(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)carbamate; 2-(4-fluorophenyl)-N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl) acetamide ; N-(4-(difluoro(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)benz amide; N-(4-(difluoro(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)-2-phenylacetamide; N-(4-(difluoro(5-(trifluoromethyl)-l,2,4-oxadiazol-3 -yl)methyl)phenyl) -4-fluorobenzamide ; N-(4-(difluoro(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzamide; N-(4-(difluoro(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)-2-(4-fluorophenyl)acetamide; 4-cyano-N-(4-(difluoro(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)phenyl)benzamide; N-(4-(difluoro(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)-4-methylbenzamide; N-(4-(difluoro(5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)picolinamide; N-methyl-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N,N-dimethyl-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(2-methoxyethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-allyl-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; azetidin- 1 -yl(4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)methanone; pyrrolidin- 1 -yl(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)methanone; N-(2-methoxyethyl)-N-methyl-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(cyclopropylmethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-ethyl-N-methyl-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-allyl-N-methyl-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(prop-2-yn-l-yl)-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-phenyl-4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)benzamide; tert-butyl (4-((5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)carbamate; N-(3,4-dichlorophenyl)-4-((5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(p-tolyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(3-chlorophenyl)-4-((5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(4- (dimethylamino)phenyl)-4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzamide; N-(4-(tert-butyl)phenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(m-tolyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; 4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)benzamide; N-(3-lluorophenyl)-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(2-lluorophenyl)-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(4-lluorophenyl)-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(2,4-dichlorophenyl)-4-((5-

(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzamide; N-(m-tolyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzothioamide; N-(4-(dimethylamino)phenyl)-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzothioamide; N-(3-fluorophenyl)-4-((5- (trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzothioamide; N-(4-fluorophenyl)-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzothioamide; N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; 4-fluoro-N-(4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; 4-methyl-N-(4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; N-(3-fluorobenzyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzothioamide; 3-chloro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; 1 -isopropyl-3-(4-((5-(trilluoromethyl)- 1 ,2,4-oxadiazol- 3-yl)methyl)phenyl)urea; l-(pyridin-3-yl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(4-methoxyphenyl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(p-tolyl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(4-chlorophenyl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(4-fluorophenyl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; 2-fluoro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; l-phenyl-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-ethyl-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; N-phenyl-4-(2-(5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; N-(p-tolyl)-4-(2-(5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; N-(4-chlorophenyl)-4-(2-(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; N-(pyridin-4-yl)-4-(2-(5-(tifluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; 3- (trifluoromethyl)-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; N-(2-methoxyphenyl)-4-(2-(5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; N-(pyridin-3-yl)-4-(2-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; l-(cyclopropylmethyl)-3-(4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(tert-butyl)-3-(4-((5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; phenyl (4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)carbamate; methyl (4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)carbamate; N-(4-((5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzyl)cyclopropanecarboxamide; 4-methyl-N-(4-((5-(trilluoromethyl)- 1 ,2,4-oxadiazol- 3-yl)methyl)benzyl)benzamide; 2-11 uoro-N-(4-((5-( trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl) benzyl) benzamide; 3 -fluoro-N-(4-((5-( trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzyl)benzamide; 3-chloro-N-(4-((5-( trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl) benzyl) benzamide; N-(4-((5-( trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzyl)propionamide; N-phenyl-4-(l-(5-(trifluoromethyl)-l,2,4-oxadiazol-3-

yl)cyclopropyl)benzamide; N-(p-tolyl)-4-(l-(5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)cyclopropyl)benzamide; N-(4-chlorophenyl)-4-(l-(5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)cyclopropyl)benzamide; N-(2-methoxyphenyl)-4-(l-(5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)cyclopropyl)benzamide; 3-(4-((phenylthio)methyl)benzyl)-5-(trifluoromethyl)-l,2,4-oxadiazole; 3-(4-((phenylsulfinyl)methyl)benzyl)-5-(trifluoromethyl)-l,2,4-oxadiazole; and 3-(4- ((phenylsulfonyl)methyl)benzyl)-5-(trifluoromethyl)-l,2,4-oxadiazole.

The present invention also relates to a process for preparing a compound of Formula I. A person skilled in the art can easily practice all or any of the following steps to prepare the compound of Formula I:

a. reacting a nitrile derivative of Formula (i) with hydroxylamine salt in the presence of a suitable base to obtain hydroxyl imidamide derivative of Formula (ii),

wherein, Rc is Ci-C4-alkyl; L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as define hereinabove;

b. reacting the hydroxyl imidamide derivative of Formula (ii) with an anhydride of Formula (V- a) or an acid halide of Formula (V-b) to obtain a compound of Formula (iii),

wherein, Rc is Ci-C4-alkyl; L1 is CR4R5; X is halide; and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove;

c. reacting the compound of Formula (iii) with an amine in the presence of trialkyl aluminium to obtain the compound of Formula I,

wherein, Rc is Ci-C -alkyl; L1 is CR4R5; L2 is C(=0)NR6; and R1, R2, R4, R5, R6, A1, A2, A3, and A4 are as define hereinabove;

d. reacting a nitrile derivative of Formula (iv) with hydroxylamine salt in the presence of a suitable base to obtain hydroxyl imidamide derivative of Formula (v),

Boc

(iv) (v)

wherein, L1 is CR4R5, C(=W) or CF2; and R4, R5, W, A1, A2, A3, and A4 are as define hereinabove;

e. reacting the hydroxyl imidamide derivative of Formula (v) with an anhydride of Formula (V -a) or an acid halide of Formula (V-b) to obtain a compound of Formula (vi),

O O

AA

1 (V-a)

HO" or

Y x

wherein, L1 is CR4R5, C(=W) and CF2; X is halide; and R1, R4, R5, W, A1, A2, A3, and A4 are as define hereinabove;

f. converting the compound of Formula (vi) into the compound of Formula (vii) using a suitable reagent,

wherein, L1 is CR4R5, C(=W) and CF2; and R1, R4, R5, W, A1, A2, A3, and A4 are as define hereinabove;

g. reacting the compound of Formula (vii) with a suitable reactant to obtain the compound of

Formula I,

(vii) I

wherein, the suitable reactant is acid or acid halide when L2 is NR6C(=0); L1 is CR4R5, C(=W) and CF2; and R1, R2, R4, R5, R6, W, A1, A2, A3, and A4 are as define hereinabove, and the reaction is carried out using a suitable base optionally in the presence of a suitable coupling reagent;

the suitable reactant is sulphonyl chloride when L2 is NR6; R2 is selected from the group consisting of C 1 - C 6 - h a 1 a 1 k y 1 s u 1 f n y 1 , arylsulfonyl, heteroarylsulfonyl, C3-C8- cycloalkylsulfonyl Ci-Ce-alkylsulfinyl, and C 1 -G,-al kylsulfonyl ; L1 is CR4R5, C(=W) and CF2; and R1, R4, R5, R6, W, A1, A2, A3, and A4 are as define hereinabove, and the reaction is carried out using a suitable base;

the suitable reactant is hydroxy compound when L2 is NR6C(=0); R2 is CVCValkoxy, aryloxy, heteroaryloxy, C3-Cs-heterocylyloxy, C3-Cs-cycloalkyloxy, and CVG.-haloalkoxy; L1 is

CR4R5, C(=W) and CF2; and R1, R4, R5, R6, W, A1, A2, A3, and A4 are as define hereinabove, and the reaction is carried out using a suitable reagent;

the suitable reactant is amine compound when L2 is NR6C(=0); R2 is CVCValkylamino, arylamino, heteroarylamino, C4-C8-heterocyclylamino, C 1 -G,-di al kyl am i no, C3-C8- cycloalkylamino, and C 1 - C 6 - a 1 k y 1 - C ; - C s - c y c 1 a 1 k y 1 a m i n ; L1 is CR4R5, C(=W) and CF2; and R1, R4, R5, R6, W, A1, A2, A3, and A4 are as define hereinabove, and the reaction is carried out using a suitable reagent;

h. fluorinating a compound of Formula (d) to obtain the compound of Formula (vi) using a suitable fluorinating agent,

o U _ . oUUg

g An NH g AVY IH

R1 Boc R1 Boc

(d) (vi)

wherein, L1 is CF2; Llb is C(=0); and R1, A1, A2, A3, and A4 are as define hereinabove;

i. reacting a nitrile derivative of Formula (g) with hydroxylamine salt in the presence of a suitable base to obtain hydroxyl imidamide derivative of Formula (h),

wherein, L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as define hereinabove;

j. reacting the hydroxyl imidamide derivative of Formula (h) with an anhydride of Formula (V-a) or an acid halide of Formula (V-b) to obtain a compound of Formula (i),

wherein, L1 is CR4R5; X is halide; and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove;

k. brominating the compound of Formula (i) using a suitable brominating reagent in the presence of a suitable radical initiator to obtain a compound of Formula (j),

wherein, L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove;

1. converting the compound of Formula (j) into a compound of Formula (k) using a suitable metal azide,

wherein, L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove;

m. reducing the compound of Formula (k) into a compound of Formula (1) using a suitable phosphine reagent,

(k) (1)

wherein, L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove;

n. reacting the compound of Formula (1) with a suitable reactant to obtain the compound of Formula I,

v

wherein, the suitable reactant is acid or acid halide when L2 is CR4R5; R2 is selected from the group consisting of Ci-G, -alkyl carbonyl ami no, CYOrcycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, heterocyclylcarbonylamino, and Ci CV haloalkylcarbonylamino, L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove, and the reaction is carried out using a suitable base optionally in the presence of a suitable coupling reagent;

the suitable reactant is sulphonyl chloride when L2 is CR4R5; R2 is sulfonamide; L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove, and the reaction is carried out using a suitable base;

the suitable reactant is isocyanate compound when L2 is CR4R5; and R2 is selected from the group consisting of Ci-Ce-alkylaminocarbonylamino, Ci-Ce-dialkylaminocarbonylamino, arylaminocarbonylamino, heteroarylaminocarbonylamino, and C3-C6- cycloalkylaminocarbonylamino; L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove;

the suitable reactant is chloroformate compound when L2 is CR4R5; and R2 is selected from the group consisting of Ci-Ce-alkyloxycarbonylamino, aryloxycarbonylamino, heterocycloxycarbonylamino, heteroaryloxycarbonylamino, and C3-C6- cycloalkyloxycarbonylamino; L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove, and the reaction is carried out using a suitable reagent;

o. brominating the compound of Formula (g) using a suitable brominating reagent in the presence of a suitable radical initiator to obtain a compound of Formula (m),

wherein, L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as define hereinabove;

p. reacting the compound of Formula (m) with a mercapto compound in the presence of a suitable base,

wherein, L1 is CR4R5; L2 is CFb; R2 is selected from the group consisting of CVCValkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, and CVCVhaloalkylthio; and R4, R5, A1, A2, A3, and A4 are as define hereinabove;

q. reacting a nitrile derivative of Formula (n) with hydroxylamine salt in the presence of a suitable base to obtain hydroxyl imidamide derivative of Formula (o),

wherein, L1 is CR4R5; L2 is CFb; R2 is selected from the group consisting of CVCValkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, and CVCVhaloalkylthio; and R4, R5, A1, A2, A3, and A4 are as define hereinabove;

r. reacting the hydroxyl imidamide derivative of Formula (o) with an anhydride of Formula (V-a) or an acid halide of Formula (V-b) to obtain the compound of Formula I,

wherein, L1 is CR4R5; L2 is CFb; R2 is selected from the group consisting of CVG.-alkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, and CVCVhaloalkylthio; X is halide; and R1,

R4, R5, A1, A2, A3, and A4 are as define hereinabove;

s. oxidizing a compound of Formula (p) to obtain the compound of Formula I using a suitable oxidizing reagent,

wherein, L1 is CR4R5; L2 is CFb; L2a is CF12; R2a is selected from the group consisting of Ci- C6-alkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, and Ci-Ce-haloalkylthio; R2 is selected from the group consisting of C i -O,-haloal kylsulfinyl , arylsulfinyl, heteroarylsulfinyl, C3-C8-cycloalkylsulfinyl, Ci-Ce-alkylsulfinyl, Ci-Ce-haloalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C ;-CVc yc 1 oal ky 1 su 1 fon y 1, and C i - C 6 - a 1 k y 1 s u 1 f n y 1 ; and R4, R5, A1, A2, A3, and A4 are as define hereinabove;

t. hydrolyzing an ester of Formula (q) into an acid of Formula (r) using suitable hydrolyzing agent,

wherein, Rc is Ci CX-alkyl; L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as define hereinabove;

u. the acid of Formula (r) is reacted with hydroxylamine salt in the presence of a suitable base to obtain the compound of Formula (s),

wherein, L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as define hereinabove;

v. reacting the compound of Formula (s) with an anhydride of Formula (V-a) or an acid halide of Formula (V-b) to obtain the compound of Formula (t),

wherein, L1 is CR4R5; X is halide; R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove;

w. reacting the compound of Formula (t) with an amine NFlR6R2 in the presence of a suitable coupling reagent and a suitable base to obtain the compound of Formula I,

wherein, L1 is CR4R5; L2 is C(=0)NR6; R1, R2, R4, R5, R6, A1, A2, A3, and A4 are as define hereinabove; and

x. converting a compound of Formula (u) into the compound of Formula I using a Lawesson’s reagent,

wherein, L1 is CR4R5; L2 is C(=S); R2 is selected from the group consisting of Ci-Ce-alkylamino, arylamino, heteroarylamino, C4-C8-heterocyclylamino, C i -G,-di al ky 1 am i no, C3-C8-

cycloalkylamino, and C i-Ce-alkyl- -Cx-cycloalkyl amino; L2c is C(=0); and R1, R4, R5, A1, A2, A3, and A4 are as define hereinabove.

The present invention also relates intermediate compound of Formula (ii),

wherein, L1 is -C(R4R5)- or -C(=W)-; R4 & R5 are as define hereinabove excluding hydrogen; Rc is

Cl-C4-alkyl; and A1, A2, A3, and A4 are as define hereinabove.

The present invention also relates other intermediate compounds of Formulae (vi), (vii), (k), and (t) which can be used for preparing the compound of Formula I;

wherein, L1 is -C(R4R5)- or -C(=W)-; R1 is CF3, CF2CI or CHF2 and R4, R5 A1, A2, A3, and A4 are as define hereinabove.

The compound of the present invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. The compound of the present invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form.

An anion part of the salt in case the compound of Formula I is a cationic or capable of forming a cation can be inorganic or organic. Alterntively, a cation part of the salt in case the compound of Formula I is an anionic or capable of forming anion can be inorganic or organic. Examples of inorganic anion part of the salt include but are not limited to chloride, bromide, iodide, fluoride, sulphate, phosphate, nitrate, nitrite, hydrogen carbonates, hydrogen sulphate. Examples of organic anion part of the salt include but are not limited to formate, alkanoates, carbonates, acetates, trifluoroacetate, trichloroacetate, propionate, glycolate, thiocyanate, lactate, succinate, malate, citrates, benzoates, cinnamates, oxalates, alkylsulphates, alkylsulphonates, arylsulphonates aryldisulphonates, alkylphosphonates, arylphosphonates, aryldiphosphonates, p-toluenesulphonate, and salicylate. Examples of inorganic cation part of the salt include but are not limited to alkali and alkaline earth metals. Examples of organic cation part of the salt include but are not limited to pyridine, methyl amine, imidazole, benzimidazole, hitidine, phosphazene, tetramethyl ammonium, tetrabutylammonium, choline and trimethylamine.

Metal ions in metal complexes of the compound of Formula I are especially the ions of the elements of the second main group, especially calcium and magnesium, of the third and fourth main group, especially aluminium, tin and lead, and also of the first to eighth transition groups, especially chromium, manganese, iron, cobalt, nickel, copper, zinc and others. Particular preference is given to the metal ions of the elements of the fourth period and the first to eighth transition groups. Here, the metals can be present in the various valencies that they can assume.

The compound selected from Formula I, (including ah stereoisomers, N-oxides, and salts thereof), typically may exist in more than one form. Formula I thus includes all crystalline and non -crystalline forms of the compound that Formula I represents. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term "polymorph" refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due to the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by Formula I can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by Formula I. Preparation and isolation of a particular polymorph of a compound represented by Formula I can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures.

In another embodiment the present invention relates to a composition comprising the compound of Formula I, agriculturally acceptable salts, metal complexes, constitutional isomers, stereo-isomers, diastereoisomers, enantiomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, geometric isomers, or N-oxides thereof optionally with one or more additional

active ingredient with the auxiliary such as inert carrier or any other essential ingredient such as surfactants, additives, solid diluents and liquid diluents.

The compound of Formula I and the composition according to the invention, respectively, are suitable as fungicides. They are distinguished by an outstanding effectiveness against a broad spectrum of phytopathogenic fungi, including soil-borne fungi, which derive especially from the classes of the Plasmodiophoromycetes, Peronosporomycetes (syn. Oomycetes), Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes (syn. Fungi imperfecti). Some are systemically effective and they can be used in crop protection as foliar fungicides, fungicides for seed dressing and soil fungicides. Moreover, they are suitable for controlling harmful fungi, which inter alia occur in wood or roots of plants.

The compound of Formula I and the composition according to the invention are particularly important in the control of a multitude of phytopathogenic fungi on various cultivated plants, such as cereals, e. g. wheat, rye, barley, triticale, oats or rice; beet, e. g. sugar beet or fodder beet; fruits, such as pomes, stone fruits or soft fruits, e. g. apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus fruit, such as oranges, lemons, grapefruits or mandarins; vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such as avocados, cinnamon or camphor; energy and raw material plants, such as corn, soybean, rape, sugar cane or oil palm; corn; tobacco; nuts; coffee; tea; bananas; vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broad-leaved trees or evergreens, e. g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants. Particularly, the compound of Formula I and the composition according to the invention are important in the control of phytopathogenic fungi on soybeans and on the plant propagation material, such as seeds, and the crop material of soybeans. Accordingly, the present invention also includes a composition comprising at least one compound of Formula I and seed. The amount of the compound of Formula I in the composition ranges from 0.1 gai (gram per active ingredient) to 10 kgai (kilogram per active ingredient) per 100 kg of seeds.

Preferably, the compound of Formula I and composition thereof, respectively are used for controlling a multitude of fungi on field crops, such as potatoes sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton, soybeans, rape, legumes, sunflowers, coffee or sugar cane; fruits; vines; ornamentals; or vegetables, such as cucumbers, tomatoes, beans or squashes.

The term "plant propagation material" is to be understood to denote all the generative or reproductive parts of the plant such as seeds and vegetative plant material such as cuttings and tubers (e. g. potatoes), which can be used for the multiplication of the plant. This includes seeds, roots, fruits, tubers, bulbs, rhizomes, shoots, sprouts, twigs, flowers, and other parts of plants, including seedlings and young plants, which are to be transplanted after germination or after emergence from soil.

These young plants may also be protected before transplantation by a total or partial treatment by immersion or pouring.

Preferably, treatment of plant propagation materials with the compound of Formula I, the combination and or the composition thereof, respectively, is used for controlling a multitude of fungi on cereals, such as wheat, rye, barley and oats; rice, corn, cotton, fruits, coffee, sugarcane and soybeans.

The term "cultivated plants" is to be understood as including plants which have been modified by breeding, mutagenesis or genetic engineering including but not limiting to agricultural biotech products on the market or in development (cf. http://cera-gmc.org/, see GM crop database therein). Genetically modified plants are plants, which genetic material has been so modified by the use of recombinant DNA techniques that under natural circumstances cannot readily be obtained by cross breeding, mutations or natural recombination. Typically, one or more genes have been integrated into the genetic material of a genetically modified plant in order to improve certain properties of the plant. Such genetic modifications also include but are not limited to targeted post-translational modification of protein(s), oligo-or polypeptides e. g. by glycosylation or polymer additions such as prenylated, acetylated or farnesylated moieties or PEG moieties. Plants that have been modified by breeding, mutagenesis or genetic engineering, e. g. have been rendered tolerant to applications of specific classes of herbicides, such as auxin herbicides such as dicamba or 2,4-D; bleacher herbicides such as hydroxylphenylpyruvate dioxygenase (HPPD) inhibitors or phytoene desaturase (PDS) inhibitors; acetolactate synthase (ALS) inhibitors such as sulfonyl ureas or imidazolinones; enolpyruvylshikimate-3-phosphate synthase (EPSPS) inhibitors, such as glyphosate; glutamine synthetase (GS) inhibitors such as glufosinate; protoporphyrinogen-IX oxidase inhibitors; lipid biosynthesis inhibitors such as acetyl CoA carboxylase (ACCase) inhibitors; or oxynil (i. e. bromoxynil or ioxynil) herbicides as a result of conventional methods of breeding or genetic engineering. Furthermore, plants have been made resistant to multiple classes of herbicides through multiple genetic modifications, such as resistance to both glyphosate and glufosinate or to both glyphosate and a herbicide from another class such as ALS inhibitors, HPPD inhibitors, auxin herbicides, or ACCase inhibitors. These herbicide resistance technologies are e. g. described in Pest Managem. Sci. 61, 2005, 246; 61, 2005, 258; 61, 2005, 277; 61, 2005, 269; 61, 2005, 286; 64, 2008, 326; 64, 2008, 332; Weed Sci. 57, 2009, 108; Austral. J. Agricult. Res. 58, 2007, 708; Science 316, 2007, 1 185; and references quoted therein. Several cultivated plants have been rendered tolerant to herbicides by conventional methods of breeding (mutagenesis), e. g. Clearfield® summer rape (Canola, BASF SE, Germany) being tolerant to imidazolinones, e. g. imazamox, or ExpressSun® sunflowers (DuPont, USA) being tolerant to sulfonyl ureas, e. g. tribenuron. Genetic engineering methods have been used to render cultivated plants such as soybean, cotton, corn, beets and rape, tolerant to herbicides such as glyphosate and glufosinate, some of which are commercially available under the bade names RoundupReady® (glyphosate-tolerant, Monsanto, U.S.A.), Cultivance® (imidazolinone tolerant, BASF SE, Germany) and LibertyLink® (glufosinate-tolerant, Bayer CropScience, Germany).

Furthermore, plants capable to synthesize one or more insecticidal proteins, especially those known from the bacterial genus (Bacillus), by the use of recombinant DNA techniques are within the scope of the present invention. The Bacillus are particularly from Bacillus thuringiensis, such as d-endotoxins, e. g. CrylA(b), CrylA(c), CrylF, CrylF(a2), CryllA(b), CrylllA, CrylllB(bl) or Cry9c; vegetative insecticidal proteins (VIP), e. g. VIP1, VIP2, VIP3 or VIP3A; insecticidal proteins of bacteria colonizing nematodes, e. g. Photorhabdus spp. or Xenorhabdus spp.; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins, or other insect-specific neurotoxins; toxins produced by fungi, such Streptomycetes toxins, plant lectins, such as pea or barley lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin or papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroid oxidase, ecdysteroid-IDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors or HMG-CoA-reductase; ion channel blockers, such as blockers of sodium or calcium channels; juvenile hormone esterase; diuretic hormone receptors (helicokinin receptors); stilbene synthase, bibenzyl synthase, chitinases or glucanases. In the context of the present invention these insecticidal proteins or toxins are to be understood expressly also as pre-toxins, hybrid proteins, truncated or otherwise modified proteins. Hybrid proteins are characterized by a new combination of protein domains, (see, e. g. W002/015701). Further examples of such toxins or genetically modified plants capable of synthesizing such toxins are disclosed, e. g., in EP374753, WO93/007278, W095/34656, EP427 529, EP451 878, W003/18810 und W003/52073. The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above. These insecticidal proteins contained in the genetically modified plants impart to the plants producing these proteins tolerance to harmful pests from all taxonomic groups of arthropods, especially to beetles (Coeloptera), two-winged insects (Diptera), and moths (Lepidoptera) and to nematodes (Nematoda). Genetically modified plants capable to synthesize one or more insecticidal proteins are, e. g., described in the publications mentioned above, and some of which are commercially available such as YieldGard® (corn cultivars producing the CrylAb toxin), YieldGard® Plus (corn cultivars producing CrylAb and Cry3Bbl toxins), Starlink® (corn cultivars

producing the Cry9c toxin), Herculex® RW (corn cultivars producing Cry34Abl, Cry35Abl and the enzyme phosphinothricin-N-acetyltransferase [PAT]); NuCOTN® 33B (cotton cultivars producing the CrylAc toxin), Bollgard® I (cotton cultivars producing the Cryl Ac toxin), Bollgard® II (cotton cultivars producing CrylAc and Cry2Ab2 toxins); VIPCOT® (cotton cultivars producing a VIP-toxin); NewLeaf®(potato cultivars producing the Cry3A toxin); Bt-Xtra®, NatureGard®, KnockOut®, BiteGard®, Protecta®, Btl 1 (e. g. Agrisure® CB) and Btl76 from Syngenta Seeds SAS, France, (corn cultivars producing the CrylAb toxin and PAT enyzme), MIR604 from Syngenta Seeds SAS, France (corn cultivars producing a modified version of the Cry3A toxin, c.f. WO 03/018810), MON 863 from Monsanto Europe S.A., Belgium (corn cultivars producing the Cry3Bbl toxin), IPC 531 from Monsanto Europe S.A., Belgium (cotton cultivars producing a modified version of the CrylAc toxin) and 1507 from Pioneer Overseas Corporation, Belgium (corn cultivars producing the Cryl F toxin and PAT enzyme).

Furthermore, plants capable to synthesize one or more proteins to increase the resistance or tolerance of those plants to bacterial, viral or fungal pathogens by the use of recombinant DNA techniques are also within the scope of the present invention. Examples of such proteins are the so-called "pathogenesis-related proteins" (PR proteins, see, e. g. EP392225), plant disease resistance genes (e. g. potato cultivars, which express resistance genes acting against Phytophthora infestans derived from the Mexican wild potato Solanum bulbocastanum) or T4-lysozym (e. g. potato cultivars capable of synthesizing these proteins with increased resistance against bacteria such as Erwinia amylvora). The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above.

Furthermore, plants capable to synthesize one or more proteins, by the use of recombinant DNA techniques, to increase the productivity (e. g. bio mass production, grain yield, starch content, oil content or protein content), tolerance to drought, salinity or other growth-limiting environmental factors or tolerance to pests and fungal, bacterial or viral pathogens of those plants are within the scope of the present invention.

Furthermore, plants that contain a modified amount of substances of content or new substances of content, by the use of recombinant DNA techniques, to improve human or animal nutrition, e. g. oil crops that produce health-promoting long-chain omega-3 fatty acids or unsaturated omega-9 fatty acids (e. g. Nexera® rape, DOW Agro Sciences, Canada) are also within the scope of the present invention.

Furthermore, plants that contain a modified amount of substances of content or new substances of content, by the use of recombinant DNA techniques, to improve raw material production, e. g.

potatoes that produce increased amounts of amylopectin (e. g. Amflora® potato, BASF SE, Germany) are also within the scope of the present invention.

CLAIMS:

1. A compound of Formula I,

wherein,

R1 is selected from the group consisting of Ci-C2-monohaloalkyl, Ci-C2-dihaloalkyl, C1-C2-trihaloalkyl, Ci-C2-tetrahaloalkyl, and Ci-C2-pentahaloalkyl;

A1 is CRA1 or N;

A2 is CRA2 or N;

A3 is CRA3 or N; &

A4 is CRA4 or N; wherein no more than two of A1, A2, A3 & A4 are nitrogen;

wherein, RA1, RA2, RA3, RA4, and RA5 are independently and optionally selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, CVCYalkyl, CYCYcycloalkyl, Ci-Ce-haloalkyl, Ci-Ce-hydroxy alkyl, Ci-Ce-alkoxy, C 1 -CYal koxy-C 1 -O,-al kyl , and Ci-Ce- haloalkoxy;

either RA1 and RA2 or RA3 and RA4 or both RA1 and RA2 as well as RA3 and RA4 together with the atoms to which they are attached may form a 3-, 4-, 5-, or 6- membered carbocyclic ring or ring system or 4-, 5-, or 6- membered heterocyclic ring or ring system; wherein C atom ring members of the carbocyclic or the heterocyclic ring or ring system may be replaced by C(=0) or C(=S); and heteroatom in the heterocyclic ring or ring system is selected from N, O or S(0)o -2, wherein, the carbocyclic or the heterocyclic ring or ring system may optionally further be substituted with one or more of halogen, Ci-Ce-alkyl, CYCYcycloalkyl, CVCYhaloalkyl, C 1 -CYhydroxyal kyl , CVCYalkoxy and Ci-C6-haloalkoxy;L1 is -C(R4R5)- or -C(=W)-;

L2 is a direct bond, -C(R4aR5a)-, -(NR6)0-1C(=W1)-(NR6)0-1, -C(F2)-, -C(R4aR5a)C(=0)-, -O-, -(CR4aR5a)o-2S(=0)o-2-, -N(R6)-, -(CR4aR5a)o-2C(=W1)NR6(CR4aR5a)0-2-, and -NR6S(=O)0-2-;

wherein W and W1 is O or S;

wherein, R2 is selected from the group consisting of hydrogen, halogen, cyano, nitro, amino, hydroxy, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-Cs-cycloalkyl, C3-Cs-cycloalkylalkyl, CVCYhaloalkyl, Ci-C6-alkoxy-Ci-C4-alkyl, Ci-Ce-hydroxy alkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8-halocycloalkyl, Ci-Ce-alkoxy, aryloxy, heteroaryloxy, C3-Cs-heterocylyloxy, C3-Cs-cycloalkyloxy, Ci-Ce-haloalkoxy, Ci-Ce-haloalkoxycarbonyl, Ci-Ce-alkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, Ci-Ce-haloalkylthio, C 1 - C - h a 1 a 1 k y 1 s u 1 f in y 1 , Ci-Ce-haloalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C3-Cs-cycloalkylsulfonyl Ci-Ce-alkylsulfinyl, Ci-Ce-alkylsulfonyl, Ci-Ce-alkylamino, arylamino, heteroarylamino, C4-Cs-heterocyclylamino, Ci-Ce-dialkylamino, C3-C8-cycloalkylamino, C i-Ce-alkyl-CYCVcycloalkylamino, Ci-Ce-alkylcarbonyl, Ci-Ce-alkoxycarbonyl, C3-C6-cycloalkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloxycarbonyl, Ci-Ce-alkylaminocarbonyl, C 1 -O,-dial kylam inocarbonyl , arylaminocarbonyl, heteroarylaminocarbonyl, C3-Ce-cycloalkylaminocarbonyl, C 1 -O,-al kylam i nocarbony 1 am i no, C 1 -G, -di al ky lam i nocarbonyl ami no, arylaminocarbonylamino, heteroarylaminocarbonylamino, C3-C6-cycloalkylaminocarbonylamino, Ci-Ce-alkylcarbonylamino, C3-C6-cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, heterocyclylcarbonylamino, C 1 G-haloalkylcarbonylamino, Ci-Ce-alkyloxycarbonylamino, aryloxycarbonylamino, heterocycloxycarbonylamino, heteroaryloxycarbonylamino, C3-C6-cycloalkyloxycarbonylamino , G-G>-alkoxycarbonyloxy, Ci-Ce-alkylaminocarbonyloxy, or -G>-di al ky lam i nocarbony loxy, sulfilimines, sulfoximines, sulfonamide, and sulfinamide; R2 may optionally further be substituted with one or more R7; or

R2 is phenyl, benzyl, naphthyl, a 5- or 6-membered aromatic ring, an 8- to l l-membered aromatic multi-cyclic ring system, an 8- to l l-membered aromatic fused ring system, a 5- or 6-membered heteroaromatic ring, an 8- to l l-membered heteroaromatic multi-cyclic ring system or an 8- to l l-membered heteroaromatic fused ring system; wherein the heteroatom of the heteroaromatic ring or ring system is one or more heteroatom selected from N, O or S, and each phenyl, benzyl, aromatic or heteroaromatic ring or ring system may be optionally substituted with one or more substituents selected from R3; or

or R2 and R6 together with the atoms to which they are attached form a 4-, 5-, 6- or 7-membered nonaromatic heterocyclic ring, an 8- to l5-membered nonaromatic hetero-multicyclic ring system, an 5- to 15 membered hetero-spirocyclic ring system, or an 8- to l5-membered nonaromatic heterocyclic fused ring system, wherein the heteroatom of the nonaromatic heterocyclic ring or ring system is selected from N, O or S(0)o 2; and the C ring member of the nonaromatic heterocyclic ring or ring system may be replaced with C(=0), C(=S), C(=CR4bR5b) or C(=NR6a) and each or nonaromatic heterocyclic ring or ring system may be optionally substituted with one or more substituents selected from R3;

wherein, R3 is independently selected from halogen, cyano, nitro, hydroxy, CVCYalkyl, C2- G.-alkenyl, C2-C6-alkynyl, CYCYhaloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8- cycloalkyl, C3-Cs-halocycloalkyl, C ; - C s - c y c 1 a 1 k y 1 - C 1 - C 6 - a 1 k y 1 , C3-C8-cycloalkyl-C3-Cs- cycloalkyl, C3-Cs-cycloalkenyl, Ci-Ce-alkoxy-Ci-Ce-alkyl, Cx-Cx-cycloalkoxy-Ci-G, -alkyl, C i -C ,-al kylsulfinyl -C i -G,-al kyl , C i -O,-al ky 1 su Ifonyl -C i -G,-al ky 1, Ci-Ce-alkylamino, di-Ci-Ce-alkylamino, Ci-Ce-alkylamino-Ci-Ce-alkyl, di-C i-CValkylamino-C i-G.-alkyl, Ci-Ce-haloalkylamino-Ci-Ce-alkyl, C3-Cs-cycloalkylamino, CVCx-cycloal kylam ino-C i -G,-al kyl , Ci-Ce-alkylcarbonyl, C i -O,-haloal koxy-C i -G,-al kyl , Ci-Ce-hydroxy alkyl, C2-C6-hydroxyalkenyl, C2-C6-hydroxyalkynyl, C2-C6-alkenyloxy, C2-C6-haloalkenyloxy, C2-C6-alkynyloxy, Ci-Ce-alkylcarbonylalkoxy, Ci-Ce-alkylthio, Ci-Ce-haloalkylthio, C3-Cs-cycloalkylthio, Ci-Ce-alkylsulfinyl, C i - C 6 - h a 1 o a 1 k y 1 s u 1 f i n y 1, Ci-Ce-alkylsulfonyl, C i -O,-haloal kylsu Ifonyl , C3-C8-cycloalkylsulfonyl, C3-Cs-cycloalkylsulfinyl, C 1 - C 6 - a 1 k y 1 s u 1 f o n y 1 a m i n , C 1 -CV haloalkylsulfonylamino, C 1 -G.-alkylsulfonyloxy, C 6 - C 10 - a 1 y 1 s u 1 f n y 1 o x y , Ce-Cio-arylsulfonyl, Ce-Cio-arylsulfinyl, Ce-Cio-arylthio, CVCVcyanoalkyl, CVCVhaloal kyl amino, Ci-Ce-alkoxyamino, Ci-Ce-haloalkoxyamino, Ci-Ce-alkoxycarbonylamino, Ci-Ce-alkylcarbonyl-Ci-Ce-alkylamino, C2-C6-alkenylthio, di(Ci-C6-haloalkyl)amino-Ci-C6-alkyl, CVCV alkylaminocarbonylamino, di(Ci-C6-haloalkyl)amino, sulfilimines, sulfoximines or SF5; wherein, R3 may be optionally substituted with halogen, cyano, amino, CVCValkyl, C 1 -CV alkoxy, C 1 -C ,-al kylam i no-C 1 -C ,-al koxy, Ci-Ce-alkylthio, and C3-Cs-cycloalkyl; or

R7 is selected from the group consisting of C i-CValkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C3-Cs-cycloalkylalkyl, Ci-Ce-haloalkyl, Ci-C6-alkoxy-Ci-C4-alkyl, Ci-Ce-hydroxy alkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-Cs-halocycloalkyl, Ci-Ce-alkoxy, C3-Cs-cycloalkyloxy, aryloxy, CVG.-haloalkoxy, and Ci-Ce-haloalkoxycarbonyl; or

two R7 together with the atoms to which they are attached may form a 3-, 4-, 5-, or 6-membered carbocyclic ring or ring system or 4-, 5-, or 6- membered heterocyclic ring or ring system; wherein C atom ring members of the carbocyclic or the heterocyclic ring or ring system may be replaced by C(=0) or C(=S); and heteroatom in the heterocyclic ring or ring system is selected from N, O or S; or

R7 is phenyl, benzyl, a 5-membered aromatic ring, a 5- or 6-membered heteroaromatic ring; wherein heteroatom of the heteroaromatic ring is selected from N, O or S; or

R7 is a 3- to 7-membered nonaromatic carbocyclic ring, a 4-, 5-, 6- or 7-membered nonaromatic heterocyclic ring, wherein, the heteroatom of the nonaromatic heterocyclic ring is selected from N, O or S(0)o -2, and the C ring member of the nonaromatic carbocyclic or nonaromatic heterocyclic ring may be replaced with C(=0), C(=S), C(=CR4cR5c) or C(=NR6b);

wherein, R7 may be further substituted with one or more R4d on C atom and with one or more R6C on N atom;

R4, R4a, R4b, R4c, R4d, R5, R5a, R5b, and R5c are independently selected from hydrogen, halogen, cyano, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, C2-C4- haloalkenyl, C2-C4-haloalkynyl, CYCVcycloalkyl, CY C - h a 1 c y c 1 a 1 k y 1 , C3-C8- cycloalkyloxy, Ci-C4-alkoxy, and Ci-C4-haloalkoxy; or

all or either of R4 and R5; R4a and R5a; R4b and R5b; and R4c and R5c; together with the atoms to which they are attached may form a C3-C6 non-aromatic carbocylic ring or C3-C6 non-aromatic heterocylic ring;

R6, R6a, R6b, and R6c are independently selected from the group consisting of hydrogen, cyano, hydroxy, NRbRc, (C=0)-Rd, (C=0)(C=0)-Rd, S(0)o 2Re, CYCY alkyl, Ci Ce-haloalkyl, Ci Ce-alkoxy, Ci Ce-haloalkoxy, Ci CYalkylamino, di-CiXY alkylamino, tri-Ci-Ce-alkylamino, and C3 Cs-cycloalkyl;

Rb and Rc represent hydrogen, hydroxyl, cyano, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, C3-Cs-cycloalkyl, aryl, heteroaryl, C4-C6-heterocyclyl, and C3- C8-halocycloalkyl;

Rd represents hydrogen, hydroxy, halogen, NRbRc, Ci-Ce-alkyl, CiXY haloalkyl, Ci Ce-alkoxy, Ci-Ce-haloalkoxy, C3-Cs-cycloalkyl aryloxy, heteroaryloxy, C3-Cs-cycloalkoxy, and C3-Cs-halocycloalkyl; and

Re represents hydrogen, halogen, cyano, CYCYalkyl, Ci-Ce-haloalkyl, Ci-Ce- alkoxy, Ci-Ce-haloalkoxy, C3-Cs-cycloalkyl, and C3-Cs-halocycloalkyl;

or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof, provided the following compounds are excluded from the definition of Formula I:

N-[4-[[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]methyl]phenyl]-methanesulfonamide [Cas No.

1128079-05-9],

N-[4-[[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]methyl]phenyl]-acetamide [Cas No. 943828-64-6], l,2,4-Oxadiazole, 3-[(2,6-dichloro-4-hydrazinylphenyl)methyl]-5-(trifluoromethyl) [Cas No. 164157- 03-3], and

4-[[5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl]methyl]-benzoic acid methyl ester [Cas No. 2368917-79- 5].

l,2,4-Oxadiazole, 3-[(4-methoxyphenyl)methyl]-5-(trifluoromethyl) [Cas No. 2322048-55-3],

2. The compound as claimed in claim 1, wherein

R1 is Ci-C2-dihaloalkyl or Ci-C2-trihaloalkyl;

A1 is CRA1 or N;

A2 is CRA2 or N;

A3 is CRA3 or N; &

A4 is CRA4 or N; wherein no more than one of A1, A2, A3 & A4 are nitrogen;

wherein, RA1, RA2, RA3, RA4, and RA5 are independently and optionally selected from the group consisting of hydrogen, halogen, cyano, CVCValkyl, C3-C6-cycloalkyl, CVCVhaloalkyl, and CVCValkoxy;

L1 is -C(R4R5)- or -C(=W)-;

L2 is -(NR6)o iC(=W ' )-(NR6)o , , -(CR4aRV i 2S(=0)o 2-, -(CR4aR5a)o-2C(=W1)NR6(CR4aR5a)0-2-, and NR6-NR6S(=0)O-2-;

wherein W and W1 is O or S;

wherein, R2 is selected from the group consisting of CVCValkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8- cycloalkyl, CVCVcycloal kylal kyl , CVCVhaloalkyl, Ci-C6-alkoxy-Ci-C4-alkyl, Ci-Ce-hydroxyalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, CVCVhalocycloalkyl, Ci-Ce-alkoxy, aryloxy, heteroaryloxy, Cs-Cs-heterocylyloxy, C3-Cs-cycloalkyloxy, Ci-Ce-alkylthio, arylthio, heteroarylthio, C4-C8- heterocyclylamino, Ci-Ce-dialkylamino, and C3-C8-cycloalkylamino; or

R2 is phenyl, benzyl, a 5- or 6-membered heteroaromatic ring; wherein the heteroatom of the heteroaromatic ring is one or more heteroatom selected from N, O or S, and each phenyl, benzyl or heteroaromatic ring may be optionally substituted with one or more substituents selected from R3; or

or R2 and R6 together with the atoms to which they are attached form a 4-, 5- or 6- membered nonaromatic heterocyclic ring, wherein the heteroatom of the nonaromatic heterocyclic ring is selected from N or O; and nonaromatic heterocyclic ring may be optionally substituted with one or more substituents selected from R3;

wherein, R3 is independently selected from halogen, cyano, CVCValkyl, C2-C6-alkenyl, C2- CValkynyl, CVCVhaloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-Cs-cycloalkyl, C3-C8- halocycloalkyl, CVCValkyl ami no, d i - C 1 - C 6 - a 1 k y 1 a m i n , and CVCValkoxy; or R4, R4a, R4b, R5, R5a and R5b are independently selected from hydrogen, halogen, Ci- C4-alkyl, Ci-C4-haloalkyl, C2-C4-haloalkenyl, C3-O, -cycloalkyl, C3-C6- halocycloalkyl, C3-Cs-cycloalkyloxy, Ci-C4-alkoxy, and Ci-C4-haloalkoxy; or

all or either of R4 and R5; R4a and R5a; and R4b and R5b; together with the atoms to which they are attached may form a C3-C6 non-aromatic carbocylic ring or C3-C6 non aromatic heterocylic ring;

R6 and R6a are independently selected from the group consisting of hydrogen, S(0)o 2Re, Ci-Ce-alkyl, Ci Ce-haloalkyl, Ci Ce-alkoxy, Ci Ce-haloalkoxy, and C3 C8- cycloalkyl;

Re represents hydrogen, Ci-Ce-alkyl, CVCVhaloalkyl, Ci-Ce-alkoxy, Ci-Ce- haloalkoxy, C3-C8-cycloalkyl, and C3-C8-halocycloalkyl;

or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof.

3. The compound as claimed in claim 1, wherein

R1 is Ci-C2-trihaloalkyl;

A1 is CH;

A2 is CH;

A3 is CH; &

A4 is CH;

L1 is -C(R4R5)- or -C(=W)-;

L2 is -(NR6)o-iC(=W1)-(NR6)0-i, -(CR4aR¾) , 2S(=0)o 2-, -(CR4aR5a)o-2C(=W1)NR6(CR4aR5a)0-2-, and NR6-NR6S(=0)O-2-;

wherein W and W1 is O or S;

wherein, R2 is selected from the group consisting of CVCValkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8- cycloalkyl, C3-Cs-cycloalkylalkyl, Ci-Ce-haloalkyl, Ci-C6-alkoxy-Ci-C4-alkyl, Ci-Ce-alkoxy, aryloxy, heteroaryloxy, C3-Cs-heterocylyloxy, C4-C8-heterocyclylamino, and Ci-Ce-dialkylamino; or

R2 is phenyl, benzyl, a 5- or 6-membered heteroaromatic ring; wherein the heteroatom of the heteroaromatic ring is one or more heteroatom selected from N, O or S, and each phenyl, benzyl or heteroaromatic ring may be optionally substituted with one or more substituents selected from R3; or or R2 and R6 together with the atoms to which they are attached form a 4-, 5- or 6- membered nonaromatic heterocyclic ring, wherein the heteroatom of the nonaromatic heterocyclic ring is selected from N or O; and nonaromatic heterocyclic ring may be optionally substituted with one or more substituents selected from R3;

wherein, R3 is independently selected from halogen, cyano, CVCValkyl, CVCVhaloalkyl, C3- C8-cycloalkyl, CVCValkyl ami no, di -C 1 -CVal ky 1 am i no, and CVCValkoxy; or

R4, R4a, R4b, R5, R5a and R5b are independently selected from hydrogen, halogen, Ci- C4-alkyl, Ci-C4-haloalkyl, CVCVcycloalkyl, C; - C 6 - h a 1 o c y c 1 a 1 k y 1 , C3-C8- cycloalkyloxy, Ci-C4-alkoxy and Ci-C4-haloalkoxy; or

all or either of R4 and R5; R4a and R5a; and R4b and R5b; together with the atoms to which they are attached may form a C3-C6 non-aromatic carbocylic ring;

R6 and R6a are independently selected from the group consisting of hydrogen, C 1 -CV alkyl, Ci CVhaloalkyl, and C3 Cs-cycloalkyl;

or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof.

4. The compound as claimed in claim 1 is selected from the group consisting of:

4-methyl-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzamide; N-(4-((5- (trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)benzamide; N-(4-((5-(trifluoromethyl)- l,2,4-oxadiazol-3-yl)methyl)phenyl)picolinamide; N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)nicotinamide; N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)isonicotinamide; 2-phenyl-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)acetamide; 4-cyano-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)benzamide; 4-(trifluoromethyl)-N-(4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3- yl)methyl)phenyl)benzamide; 4-fluoro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)benzamide; 4-chloro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)benzamide; 2-(4-fluorophenyl)-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)acetamide ; N-(4-fluorobenzyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; morpholino(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)phenyl)methanone ; N-(3-fluorobenzyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(l-(p-tolyl)ethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(pyridin-3-ylmethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(5-chloropyridin-3-yl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(2-chloro-5-methoxyphenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benz amide; N-(2-methoxyphenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-

yl)methyl)benzamide; N-(4-methoxyphenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(2-morpholinoethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(4-chlorophenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(3-fluorobenzyl)-N-methyl-4-((5-(triiluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(isoxazol-3-yl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; 4-methoxy-N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl)benzamide; 4-chloro-N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl)benzamide; N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl)isonicotinamide; N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl)nicotinamide; tert-butyl (4-(5-(trifluoromethyl)- 1 ,2,4-oxadiazole-3-carbonyl)phenyl)carbamate; tert-butyl (4-(difluoro(5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)carbamate; 2-(4-fluorophenyl)-N-(4-(5-(trifluoromethyl)-l,2,4-oxadiazole-3-carbonyl)phenyl) acetamide; N-(4-(difluoro(5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)benzamide; N-(4-(diiluoro(5-(triiluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)-2-phenylacetamide; N-(4-(difluoro(5-(tifluoromethyl)-l,2,4-oxadiazol-3 -yl)methyl)phenyl) -4-fluorobenzamide ; N -(4-(difluoro(5 -(tifluoromethyl) -1,2,4-oxadiazol-3-yl)methyl)phenyl)benzamide; N-(4-(difluoro(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)-2-(4-fluorophenyl)acetamide; 4-cyano-N-(4-(difluoro(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)phenyl)benzamide; N-(4-(difluoro(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)-4-methylbenzamide; N-(4-(difluoro(5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)picolinamide; N-methyl-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N,N-dimethyl-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(2-methoxyethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-allyl-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; azetidin- 1 -yl(4-((5-(tifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)methanone; pyrrolidin- 1 -yl(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)methanone; N-(2-methoxyethyl)-N-methyl-4-((5-(tifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(cyclopropylmethyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-ethyl-N-methyl-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-allyl-N-methyl-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(prop-2-yn-l-yl)-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-phenyl-4-((5-(tifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)benzamide; tert-butyl (4-((5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)carbamate; N-(3,4-dichlorophenyl)-4-((5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(p-tolyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(3-chlorophenyl)-4-((5-(trilluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(4- (dimethylamino)phenyl)-4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzamide; N-(4-

(tert-butyl)phenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzamide; N-(m-tolyl)-4- ((5 -(trifluoromethyl) -1,2 ,4-oxadiazol-3 -yl)methyl)benzamide ; 4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)-N-(3-(trifluoromethyl)phenyl)benzamide; N-(3-fluorophenyl)-4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzamide; N-(2-fluorophenyl)-4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzamide; N-(4-fluorophenyl)-4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzamide; N-(2,4-dichlorophenyl)-4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)benzamide; N-(m-tolyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzothioamide; N-(4-(dimethylamino)phenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzothioamide; N-(3-fluorophenyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzothioamide; N-(4-fluorophenyl)-4-((5- (trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzothioamide; N-(4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; 4-fluoro-N-(4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; 4-methyl-N-(4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; N-(3-fluorobenzyl)-4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)benzothioamide; 3-chloro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; 1 -isopropyl-3-(4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol- 3-yl)methyl)phenyl)urea; l-(pyridin-3-yl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(4-methoxyphenyl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(p-tolyl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(4-chlorophenyl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(4-fluorophenyl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; 2-fluoro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; l-phenyl-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-ethyl-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; N-phenyl-4-(2-(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; N-(p-tolyl)-4-(2-(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; N-(4-chlorophenyl)-4-(2-(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; N-(pyridin-4-yl)-4-(2-(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; 3- (trifluoromethyl)-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)benzenesulfonamide; N-(2-methoxyphenyl)-4-(2-(5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; N-(pyridin-3-yl)-4-(2-(5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)propan-2-yl)benzamide; l-(cyclopropylmethyl)-3-(4-((5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl)methyl)phenyl)urea; l-(tert-butyl)-3-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl)methyl)phenyl)urea; phenyl (4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)carbamate; methyl (4-((5-(trifluoromethyl)- 1 ,2,4-oxadiazol-3-yl)methyl)phenyl)carbamate; N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3-

yl)methyl)benzyl)cyclopropanecarboxamide; 4-methyl-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol- 3 -yl)methyl)benzyl)benzamide ; 2-fluoro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl) benzyl) benzamide ; 3-fluoro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl) benzyl) benzamide ; 3-chloro-N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl) benzyl) benzamide ; N-(4-((5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)methyl)benzyl)propionamide; N-phenyl-4-(l-(5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)cyclopropyl)benzamide ; N-(p-tolyl)-4-(l-(5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)cyclopropyl)benzamide ; N-(4-chlorophenyl)-4-(l-(5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)cyclopropyl)benzamide; N-(2-methoxyphenyl)-4-(l-(5-(trifluoromethyl)-l,2,4-oxadiazol-3- yl)cyclopropyl)benzamide; 3-(4-((phenylthio)methyl)benzyl)-5-(trifluoromethyl)-l,2,4-oxadiazole; 3-(4-((phenylsulfinyl)methyl)benzyl)-5-(trifluoromethyl)-l,2,4-oxadiazole; and 3-(4- ((phenylsulfonyl)methyl)benzyl)-5-(trifluoromethyl)-l,2,4-oxadiazole.

5. The compound as claimed in claim 1 in a combination with at least one further pesticidally active substance selected from the group consisting of fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, safeners, plant growth regulators, antibiotics, fertilizers and nutrients.

6. The compound as claimed in claim 1 in a composition comprising at least one agrochemically acceptable auxiliary.

7. The compound as claimed in claim 6, wherein the composition further comprises at least one additional active ingredient.

8. The compound as claimed in claim 1 in a composition applied to seed, wherein the amount of the compound of the formula I is from 0.1 gai to 10 kgai per 100 kg of seeds.

9. The compound as claimed in claim 1 used in a method for controlling or preventing phytopathogenic fungi, wherein the method comprises treating the fungi or the materials, plants, plant parts, locus thereof, soil or seeds to be protected against fungal attack, with an effective amount of at least one compound of formula I claimed in claim 1 or the combination claimed in claim 5 or the composition claimed in claim 6.

10. The compound as claimed in claim 1 used in a method for controlling or preventing infestation of plants by phytopathogenic micro-organisms in agricultural crops and or horticultural crops wherein an effective amount of at least one compound of formula I claimed in claim 1 or the combination claimed in claim 5 or the composition claimed in claim 6, is applied to the seeds of plants.

11. The compound as claimed in claim 1, 5 and 6, for controlling or preventing plant diseases.

12. The compound as claimed in claims 1, 5 and 6, used as fungicides.

13. The compound as claimed in claim 9, wherein the plant diseases are rust pathogens selected from the group consisting of Puccinia spp. (rusts), comprising P. triticina (brown or leaf rust), P. striiformis (stripe or yellow rust), P. hordei (dwarf rust), P. graminis (stem or black rust) and P. recondita (brown or leaf rust) on cereals viz., wheat, barley or rye; P. melanocephala on sugarcane and Phakopsora spp. comprising Phakopsora pachyrhizi and P. meibomiae on soybeans, Hemileia vastatrix (Coffee rust), Uromyces spp., comprising Ufabae (rust of beans).

14. A process for preparing a compound of Formula I as claimed in claim 1, said process comprising any of the steps of:

a. reacting a nitrile derivative of Formula (i) with hydroxylamine salt in the presence of a suitable base to obtain hydroxyl imidamide derivative of Formula (ii),

0) (ϋ)

wherein, Rc is Ci-C4-alkyl; L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as defined in claim 1;

b. reacting the hydroxyl imidamide derivative of Formula (ii) with an anhydride of Formula (V- a) or an acid halide of Formula (V-b) to obtain a compound of Formula (iii),

wherein, Rc is Ci-C4-alkyl; L1 is CR4R5; X is halide; and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1 ;

c. reacting the compound of Formula (iii) with an amine in the presence of trialkyl aluminium to obtain the compound of Formula I,

(iii) I

wherein, Rc is Ci-C -alkyl; L1 is CR4R5; L2 is C(=0)NR6; and R1, R2, R4, R5, R6, A1, A2, A3, and A4 are as defined in claim 1 ;

d. reacting a nitrile derivative of Formula (iv) with hydroxylamine salt in the presence of a suitable base to obtain hydroxyl imidamide derivative of Formula (v),

Boc

(iv) (V)

wherein, L1 is CR4R5, C(=W) or CF2; and R4, R5, W, A1, A2, A3, and A4 are as defined in claim l ;

e. reacting the hydroxyl imidamide derivative of Formula (v) with an anhydride of Formula (V-a) or an acid halide of Formula (V-b) to obtain a compound of Formula (vi),

wherein, L1 is CR4R5, C(=W) and CF2; X is halide; and R1, R4, R5, W, A1, A2, A3, and A4 are as defined in claim 1 ;

f. converting the compound of Formula (vi) into the compound of Formula (vii) using a suitable reagent,

wherein, L1 is CR4R5, C(=W) and CF2; and R1, R4, R5, W, A1, A2, A3, and A4 are as defined in claim 1 ;

g. reacting the compound of Formula (vii) with a suitable reactant to obtain the compound of

Formula I,

(vii) I

wherein, the suitable reactant is acid or acid halide when L2 is NR6C(=0); L1 is CR4R5, C(=W) and CF2; and R1, R2, R4, R5, R6, W, A1, A2, A3, and A4 are as defined in claim 1, and the reaction is carried out using a suitable base optionally in the presence of a suitable coupling reagent;

the suitable reactant is sulphonyl chloride when L2 is NR6; R2 is selected from the group consisting of C 1 - C 6 - h a 1 a 1 k y 1 s u 1 f n y 1 , arylsulfonyl, heteroarylsulfonyl, C3-C8- cycloalkylsulfonyl Ci-Ce-alkylsulfinyl, and C 1 -G,-al kylsulfonyl ; L1 is CR4R5, C(=W) and CF2; and R1, R4, R5, R6, W, A1, A2, A3, and A4 are as defined in claim 1, and the reaction is carried out using a suitable base;

the suitable reactant is hydroxy compound when L2 is NR6C(=0); R2 is CVCValkoxy, aryloxy, heteroaryloxy, C3-Cs-heterocylyloxy, C3-Cs-cycloalkyloxy, and CVG.-haloalkoxy; L1 is

CR4R5, C(=W) and CF2; and R1, R4, R5, R6, W, A1, A2, A3, and A4 are as defined in claim 1, and the reaction is carried out using a suitable reagent;

the suitable reactant is amine compound when L2 is NR6C(=0); R2 is CVCValkylamino, arylamino, heteroarylamino, C4-C8-heterocyclylamino, C 1 -G,-di al kyl am i no, C3-C8- cycloalkylamino, and C 1 - C 6 - a 1 k y 1 - C ; - C s - c y c 1 a 1 k y 1 a m i n ; L1 is CR4R5, C(=W) and CF2; and R1, R4, R5, R6, W, A1, A2, A3, and A4 are as defined in claim 1, and the reaction is carried out using a suitable reagent;

h. fluorinating a compound of Formula (d) to obtain the compound of Formula (vi) using a suitable fluorinating agent,

o U _ . oUUg

g* An NH A A IH

R1 Boc R1 Boc

(d) (vi)

wherein, L1 is CF2; Llb is C(=0); and R1, A1, A2, A3, and A4 are as defined in claim 1 ;

i. reacting a nitrile derivative of Formula (g) with hydroxylamine salt in the presence of a suitable base to obtain hydroxyl imidamide derivative of Formula (h),

wherein, L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as defined in claim 1;

j. reacting the hydroxyl imidamide derivative of Formula (h) with an anhydride of Formula (V-a) or an acid halide of Formula (V-b) to obtain a compound of Formula (i),

wherein, L1 is CR4R5; X is halide; and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1 ;

k. brominating the compound of Formula (i) using a suitable brominating reagent in the presence of a suitable radical initiator to obtain a compound of Formula (j),

wherein, L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1;

1. converting the compound of Formula (j) into a compound of Formula (k) using a suitable metal azide,

wherein, L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1;

m. reducing the compound of Formula (k) into a compound of Formula (1) using a suitable phosphine reagent,

(k) (1)

wherein, L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1;

n. reacting the compound of Formula (1) with a suitable reactant to obtain the compound of Formula I,

v

wherein, the suitable reactant is acid or acid halide when L2 is CR4R5; R2 is selected from the group consisting of Ci-G, -alkyl carbonyl ami no, CYOrcycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, heterocyclylcarbonylamino, and C i CV haloalkylcarbonylamino, L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim

1 , and the reaction is carried out using a suitable base optionally in the presence of a suitable coupling reagent;

the suitable reactant is sulphonyl chloride when L2 is CR4R5; R2 is sulfonamide; L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1, and the reaction is carried out using a suitable base;

the suitable reactant is isocyanate compound when L2 is CR4R5; and R2 is selected from the group consisting of Ci-Ce-alkylaminocarbonylamino, Ci-Ce-dialkylaminocarbonylamino, arylaminocarbonylamino, heteroarylaminocarbonylamino, and C3-C6- cycloalkylaminocarbonylamino; L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1 ;

the suitable reactant is chloroformate compound when L2 is CR4R5; and R2 is selected from the group consisting of Ci-Ce-alkyloxycarbonylamino, aryloxycarbonylamino, heterocycloxycarbonylamino, heteroaryloxycarbonylamino, and C3-C6- cycloalkyloxycarbonylamino; L1 is CR4R5; and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1 , and the reaction is carried out using a suitable reagent;

o. brominating the compound of Formula (g) using a suitable brominating reagent in the presence of a suitable radical initiator to obtain a compound of Formula (m),

wherein, L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as defined in claim 1;

p. reacting the compound of Formula (m) with a mercapto compound in the presence of a suitable base,

wherein, L1 is CR4R5; L2 is CFb; R2 is selected from the group consisting of CVCValkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, and CVCVhaloalkylthio; and R4, R5, A1, A2, A3, and A4 are as defined in claim 1 ;

q. reacting a nitrile derivative of Formula (n) with hydroxylamine salt in the presence of a suitable base to obtain hydroxyl imidamide derivative of Formula (o),

wherein, L1 is CR4R5; L2 is CFb; R2 is selected from the group consisting of CVCValkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, and CVCVhaloalkylthio; and R4, R5, A1, A2, A3, and A4 are as defined in claim 1 ;

r. reacting the hydroxyl imidamide derivative of Formula (o) with an anhydride of Formula (V -a) or an acid halide of Formula (V-b) to obtain the compound of Formula I,

wherein, L1 is CR4R5; L2 is CFb; R2 is selected from the group consisting of CVCValkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, and Ci-Ce-haloalkylthio; X is halide; and R1,

R4, R5, A1, A2, A3, and A4 are as defined in claim 1;

s. oxidizing a compound of Formula (p) to obtain the compound of Formula I using a suitable oxidizing reagent,

wherein, L1 is CR4R5; L2 is CFb; L2a is CFb; R2a is selected from the group consisting of Ci- Ce-alkylthio, arylthio, heteroarylthio, C4-C5-heterocyclylthio, and Ci-Ce-haloalkylthio; R2 is selected from the group consisting of Ci-Ce-haloalkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, C3-C8-cycloalkylsulfinyl, Ci-Ce-alkylsulfinyl, Ci-Ce-haloalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, C ;-C c-c yc 1 oal ky 1 su 1 fon y 1 , and C i - C 6 - a 1 k y 1 s u 1 f n y 1 ; and R4, R5, A1, A2, A3, and A4 are as defined in claim 1 ;

t. hydrolyzing an ester of Formula (q) into an acid of Formula (r) using suitable hydrolyzing agent,

wherein, Rc is Ci CX-alkyl; L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as defined in claim l ;

u. the acid of Formula (r) is reacted with hydroxylamine salt in the presence of a suitable base to obtain the compound of Formula (s),

wherein, L1 is CR4R5; and R4, R5, A1, A2, A3, and A4 are as defined in claim 1;

v. reacting the compound of Formula (s) with an anhydride of Formula (V-a) or an acid halide of Formula (V-b) to obtain the compound of Formula (t),

wherein, L1 is CR4R5; X is halide; R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1;

w. reacting the compound of Formula (t) with an amine NFlR6R2 in the presence of a suitable coupling reagent and a suitable base to obtain the compound of Formula I,

wherein, L1 is CR4R5; L2 is C(=0)NR6; R1, R2, R4, R5, R6, A1, A2, A3, and A4 are as defined in claim 1 ; and

x. converting a compound of Formula (u) into the compound of Formula I using a Lawesson’s reagent,

wherein, L1 is CR4R5; L2 is C(=S); R2 is selected from the group consisting of Ci-Ce-alkylamino, arylamino, heteroarylamino, C4-C8-heterocyclylamino, C i -G,-di al ky 1 am i no, C3-C8-

cycloalkylamino, and C i-CValkyl-CYCVcycloalkyl amino; L2c is C(=0); and R1, R4, R5, A1, A2, A3, and A4 are as defined in claim 1.

15. A Compound of Formula (ii),

wherein, L1 is -C(R4R5)- or -C(=W)-; R4 & R5 are as defined in claim 1 excluding hydrogen; Rc i Cl-C4-alkyl; and A1, A2, A3, and A4 are as defined in claim 1.

16. A compound of Formula (vi),

wherein, L1 is -C(R4R5)- or -C(=W)-; R1 is CF3, CF2CI or CFn¾ and R4, R5 A1, A2, A3, and A4 are as defined in claim 1.

17. A compound of Formula (vii),

wherein, L1 is -C(R4R5)- or -C(=W)-; R1 is CF3, CF2CI or CFn¾ and R4, R5 A1, A2, A3, and A4 are as defined in claim 1.

18. A compound of Formula (k),

wherein, L1 is -C(R4R5)- or -C(=W)-; R1 is CF3, CF2CI or CFn¾ and R4, R5 A1, A2, A3, and A4 are as defined in claim 1.

19. A compound of Formula (t),

wherein, L1 is -C(R4R5)- or -C(=W)-; R1 is CF3, CF2CI or CFn¾ and R4, R5 A1, A2, A3, and A4 are as defined in claim 1.